[go: up one dir, main page]

WO2000017326A1 - Cellules non hematopoietiques, y compris les cardiomyocytes et les cellules de muscle squelettique, que l'on derive de cellules souches hematopoietiques, et procedes relatifs a leur elaboration et a leur utilisation - Google Patents

Cellules non hematopoietiques, y compris les cardiomyocytes et les cellules de muscle squelettique, que l'on derive de cellules souches hematopoietiques, et procedes relatifs a leur elaboration et a leur utilisation Download PDF

Info

Publication number
WO2000017326A1
WO2000017326A1 PCT/US1999/021916 US9921916W WO0017326A1 WO 2000017326 A1 WO2000017326 A1 WO 2000017326A1 US 9921916 W US9921916 W US 9921916W WO 0017326 A1 WO0017326 A1 WO 0017326A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
cell
growth factor
stem cells
skeletal muscle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/021916
Other languages
English (en)
Inventor
Carol A. Eisenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MUSC Foundation for Research and Development
Original Assignee
MUSC Foundation for Research and Development
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MUSC Foundation for Research and Development filed Critical MUSC Foundation for Research and Development
Priority to AU60562/99A priority Critical patent/AU6056299A/en
Publication of WO2000017326A1 publication Critical patent/WO2000017326A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/113—Acidic fibroblast growth factor (aFGF, FGF-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/119—Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/135—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/148—Transforming growth factor alpha [TGF-a]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/365—Endothelin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/385—Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells

Definitions

  • the present invention is related to specific cell types, including cardiomyocytes and skeletal muscle cells, derived from either nonembryonic stem cells, such as hematopoietic stem cells, or embryonic hematopoietic stem cells, the method of derivation, and therapeutic uses of the stem cells and the cells derived from the nonembryonic stem cells and the embryonic hematopoietic stem cells.
  • nonembryonic stem cells such as hematopoietic stem cells, or embryonic hematopoietic stem cells
  • cardiac disease is the number one cause of mortality and morbidity among the United States population. Because the adult heart does not exhibit a regenerative capacity, this dysfunction is mainly due to the loss of cardiomyocytes and the infiltration of scar tissue (Soonpaa et al., 1995). Although some success has been reported in promoting adult cardiomyocyte proliferation (U.S. Patent No. 5,543,318), adult cardiomyocytes in vitro do not possess the capacity to proliferate. Thus, the loss of cardiomyocytes is irreversible.
  • organ transplantation Because of the limited availability of donor hearts, however, relatively few potential recipients can benefit from heart transplantation. Even if the problems with cardiac availability were overcome, the high costs involved in this procedure and the radical nature of the surgery would still limit organ transplantation to only those patients with end-stage diseased hearts. Thus, alternatives to organ transplantation are needed.
  • grafting of healthy cardiomyocytes into a recipient's heart has been proposed as an alternative to organ transplantation.
  • the feasibility of grafting cells into cardiac tissue has been shown in animal studies using a variety of cell populations, including skeletal myoblasts, cardiac tumor cell lines, fetal cardiomyocytes, and cardiomyocytes derived from embryonic stem (ES) cells (Klug et al, 1996; Koh et al., 1993a; Koh et al., 1993b; Koh et al., 1995; Soonpaa et al, 1994).
  • ES embryonic stem
  • transfected embryonic stem cells have been differentiated into cardiomyocyte lineage and have successfully been incorporated into cardiac tissue (U.S. Patent No.5,733, 727).
  • Embryonic cardiomyocyte grafts as used in treating heart disease, however, present certain problems. Because of the ethical issues involved, as well as various technical and availability limitations, the use of embryonic tissue is not practical. Nor can adult cardiomyocytes practically be harvested, even if proliferation can be promoted in vitro. Furthermore, these cardiomyocyte grafts from embryonic or nonembryonic donors still necessitate the use of chronic immunosuppression to prevent rejection of the graft by the recipient. Thus, alternative sources of cardiomyocytes capable of stable integration into the adult heart are needed. These sources ideally would provide the potential of deriving the donor cells from the recipient to avoid graft rejection.
  • Embryonic myoblasts and satellite cells have generally been used as a source of skeletal muscle cells. These sources, however, present the same limitations as the available sources for cardiomyocytes.
  • the present invention provides a method of promoting differentiation of a hematopoietic stem cell into a cell of non-hematopoietic lineage, comprising the steps of obtaining a hematopoietic stem cell with non-hematopoietic potential from an embryonic or nonembryonic donor and contacting the stem cell with a growth factor or combination of growth factors, thereby promoting differentiation of the hematopoietic stem cell into a cell of non-hematopoietic lineage.
  • the hematopoietic stem cell is a bone marrow cell or a blood cell.
  • the present invention further provides a process of promoting differentiation of a stem cell into a cardiomyocyte or skeletal muscle cell, comprising the steps of obtaining a stem cell with cardiomyocyte or skeletal muscle cell potential from a nonembryonic donor or a hematopoietic stem cell from an embryonic donor and contacting the stem cell with a growth factor or combination of growth factors, thereby promoting differentiation of the stem cell into the cardiomyocyte.
  • the stem cell is a bone marrow cell or blood cell, more preferably a hematopoietic stem cell, and even more preferably a myeloid-lymphoid stem cell (including, for example, a myeloid-lymphoid stem cell intermediate).
  • compositions comprising stem cells with cardiomyocyte or skeletal muscle cell potential derived from a nonembryonic donor or hematopoietic stem cells with cardiomyocyte or skeletal muscle cell potential derived from an embryonic donor and Wnt (e.g., a member of the class Wnt5a, including e.g., Wnt 11 ), retinoic acid, basic fibroblast factor, fibroblast growth factor-4, dexamethasone, bone morphogenic factor -4, and either acidic fibroblast growth factor or endothelial cell growth factor in amounts to promote the differentiation of the stem cells into cardiomyocytes.
  • Wnt e.g., a member of the class Wnt5a, including e.g., Wnt 11
  • retinoic acid retinoic acid
  • basic fibroblast factor fibroblast growth factor-4
  • dexamethasone dexamethasone
  • bone morphogenic factor -4 amethasone
  • composition further comprising stem cell factor, endothelin-1, transforming growth factor beta, interleukin (including, e.g., IL-2, IL-10 and 11-15), and a PKC inhibitor (e.g., sphingosine).
  • the invention also provides as an alternative embodiment, a composition, comprising stem cells with cardiomyocyte or skeletal muscle cell potential derived from a nonembryonic donor or hematopoietic stem cells from an embryonic donor and stem cell factor, transforming growth factor beta, endothelin-1, and either basic fibroblast growth factor or endothelial cell growth factor in amounts to promote the differentiation of the stem cells into skeletal muscle cells.
  • composition further comprising retinoic acid, interleukin (including, e.g., IL-2 and 11-15), insulin- like growth factor- 1, platelet derived growth factor dexamethasone, angiotensin II, 3,3',5-triiodo-L-thyronine, and hyaluronic acid.
  • interleukin including, e.g., IL-2 and 11-15
  • insulin- like growth factor- 1 insulin- like growth factor- 1
  • platelet derived growth factor dexamethasone insulin- like growth factor- 1
  • angiotensin II 3,3',5-triiodo-L-thyronine
  • hyaluronic acid hyaluronic acid
  • the present invention also provides a method of determining whether nonembryonic stem cells or embryonic hematopoietic stem cells of unknown cardiomyocyte or skeletal muscle cell potential can be promoted to differentiate into cardiomyocytes or skeletal muscle cells, comprising the steps of contacting the stem cells with a growth factor or combination of growth factors under conditions that allow the cells to differentiate, and determining the presence of differentiated cells having one or more characteristics of cardiomyocytes or skeletal muscle cells.
  • the invention also provides a method of treating a subject with heart injury or disease, comprising transplanting the cardiomyocytes of the present invention or the stem cells with cardiomyocyte potential into the cardiac muscle of the subject, thereby improving cardiac function. Also provided is a method of treating a subject with muscle injury or disease, comprising transplanting the skeletal muscle cells of the present invention or the stem cells with skeletal muscle cell potential into the skeletal muscle of the subject, thereby improving skeletal muscle function.
  • an object of the present invention is to provide a source of cardiomyocytes or skeletal muscle cells for transplantation using bone marrow or blood cells in order to overcome problems with the prior art.
  • the present invention provides a method of promoting differentiation of a hematopoietic stem cell into a cell of non-hematopoietic lineage, comprising the steps of obtaining a hematopoietic stem cell with non-hematopoietic potential from a nonembryonic or embryonic donor and contacting the stem cell with a growth factor or combination of growth factors, thereby promoting differentiation of the hematopoietic stem cell into a cell of non-hematopoietic lineage.
  • the hematopoietic stem cell is a bone marrow or blood cell, including myeloid-lymphoid stem cells, myeloid- lymphoid stem cell intermediates, and monoDC progenitor (i.e., the monoblast or the DC progenitor). More preferably, the hematopoietic stem cell is a myeloid-lymphoid stem cell.
  • hematopoietic stem cells include multipotent hematopoietic stem cells, BFU-Es, GM-CFUs, GEMM-CFCs, CFCs, Bl-CFCs, NK progenitors, dendritic progenitors, T progenitors, or B progenitors.
  • a "cell of non-hematopoietic lineage” includes non-blood and non-lymph cells and precursors thereof, including, but not limited to, myoblasts and myocytes (both cardiomyocytes and skeletal muscle cells). It is understood that the stem cells of the present invention can also be directed to differentiate into other cells of non- hematopoietic lineage using similar procedures as well as into cells of hematopoietic lineage.
  • the step of contacting the stem cell with a growth factor or combination of growth factors can be performed used a defined culture medium or alternatively can be performed either in vivo or in vitro by contacting the stem cell with either cardiac tissue, skeletal muscle tissue, or any other tissue that produces environmental cues to promote differentiation of a hematopoietic cell or other stem cell into a cell of non-hematopoietic cell lineage.
  • the present invention provides a process of promoting differentiation of a stem cell into a cardiomyocyte or skeletal muscle cell, comprising the steps of obtaining a stem cell with cardiomyocyte or skeletal muscle cell potential from a nonembryonic donor and contacting the stem cell with a growth factor or combination of growth factors, thereby promoting differentiation of the stem cell into the cardiomyocyte or skeletal muscle cell.
  • stem cell with cardiomyocyte or skeletal muscle cell potential does not include embryonic stem cells, mesenchymal stem cells, satellite cells, or QCE-6 cells.
  • cardiac myocyte any cell in the cardiac myocyte lineage that shows at least one phenotypic characteristic of a cardiac muscle cell.
  • phenotypic characteristics can include expression of cardiac proteins, such as cardiac sarcomeric or myofibrillar proteins or atrial natriuretic factor, or electrophysiological characteristics.
  • Cardiac sarcomeric or myofibrillar proteins include, for example, atrial myosin heavy chain, cardiac-specific ventricular myosin heavy chain, desmin, N-cadherin, sarcomeric actin, cardiac troponin I, myosin heavy chain, and Na-K-ATPase.
  • Electrophysiological characteristic of a cardiomyocyte include, for example, transient K + channel currents, and acetylcholine and cholera toxin responses.
  • skeletal muscle cell is meant any cell in the skeletal muscle cell lineage that shows at least one phenotypic characteristic of a skeletal muscle cell.
  • Such phenotypic characteristics can include expression of skeletal muscle proteins, such as skeletal muscle-specific transcription factor MyoD or skeletal muscle-specific myosin.
  • skeletal muscle electrophysiological characteristics and morphologic characteristics are included. For example, fusion into a multinucleated striated fiber is a phenotypic characteristic of skeletal muscle.
  • promoting differentiation of the stem cell into the cardiomyocyte or skeletal muscle cell is meant inducing a stem cell to follow a cardiac muscle or skeletal muscle lineage such that the stem cell gives rise to progeny that exhibit at least one phenotypic characteristic of a cardiomyocyte or skeletal muscle cell.
  • embryonic is meant fetal or postnatal.
  • the embryonic period is considered to be early prenatal development, and specifically, in the human, the first eight weeks following fertilization.
  • the present invention excludes embryonic stem cells, embryonic cardiomyoblasts or cardiomyocytes, and embryonic skeletal myoblasts and myocytes. Certain embodiments of the present invention, however, utilize embryonic hematopoietic stem cells.
  • the cardiomyocyte derived by the present method is noncontracting but contains contractile elements.
  • noncontracting is meant non-beating. More specifically, “non-beating” or “noncontracting” means the absence of spontaneous contraction.
  • the cardiomyocytes are capable of contraction upon inducement.
  • Methods of inducing contracting include introduction of the derived cardiomyocyte into spontaneously beating cardiac muscle in vivo, whereupon the cardiomyocyte is capable of electronic coupling with the spontaneously contracting cardiac muscle and integrating into the syncytium of the cardiac muscle, thereby becoming a contracting cardiac muscle cell.
  • contraction can be induced in vitro by co-culturing the derived cardiomyocytes with contracting cardiomyocytes isolated from embryonic, fetal, or postnatal heart.
  • Contraction can also be induced by changes in ion concentration (e.g., by elevated K + ), by mechanical stimulation, or by electrical stimulation (e.g., Ingber et al., 1991; Johnson et al., 1993; McDermott et al., 1985; and Simpson et al., 1994).
  • ion concentration e.g., by elevated K +
  • mechanical stimulation e.g., by mechanical stimulation
  • electrical stimulation e.g., Ingber et al., 1991; Johnson et al., 1993; McDermott et al., 1985; and Simpson et al., 1994.
  • the myofibrillar organization is re-established, however, upon contacting the cardiomyocytes with contracting cells (e.g., cardiomyocytes) either in vivo or in vitro.
  • contracting cells e.g., cardiomyocytes
  • noncontracting cardiomyocytes of the present invention i.e., they are capable of complete myofibrillar organization and contraction when contacted with contracting myocytes.
  • Other cell types that can induce myofibrillar organization and contraction include, for example, blastodermal cells or neuronal cells (e.g., neuroblasts).
  • stem cell is meant a non-immortalized cell that possesses the capability of dividing and producing progeny that include mature, differentiated cells.
  • the stem cells used in the present method have non-hematopoietic potential, including for example, cardiomyocyte potential or skeletal muscle potential.
  • cardiomyocyte potential or “skeletal muscle cell potential” is meant the ability to give rise to progeny that can differentiate into a cardiomyocyte or skeletal muscle cell under specific conditions.
  • stem cells with cardiomyocyte or skeletal muscle cell potential include certain bone marrow or blood cells and certain hematopoietic stem cells, including myeloid-lymphoid stem cells, myeloid-lymphoid stem cell intermediates, monoDC progenitor (i.e., the monoblast or the DC progenitor).
  • the stem cell used to derive the cardiomyocyte or skeletal muscle cell is preferably a bone marrow or blood cell, and, more preferably, a hematopoietic stem cell, and even more preferably a myeloid-lymphoid stem cell.
  • the hematopoietic stem cell from which the present cardiomyocyte or skeletal muscle cell is derived is a nonadherent cell.
  • nonadherent is meant a cell that does not adhere to tissue culture plastic or that adheres loosely, so as to be easily dislodged by gentle pipetting.
  • Hematopoietic stem cells as used in the present invention can be isolated from nonembryonic donors from, e.g., the bone marrow, the spleen, the liver, and peripheral blood. Hematopoietic stem cells can be isolated from an embryonic donor from the aorta-gonad-mesonephros area, the spleen, the liver, and the bone marrow.
  • the bone marrow for example, comprises a heterogeneous population of cells at different stages of maturity. Separation of more mature cells from stem cells can be performed using any one of the techniques well known in the art, including cell density gradients (e.g., Ficoll-Paque), cell sorting using cell surface antigens (e.g., with a fluorescence activated cell sorter), or by magnetic beads (StemSep Technologies) which bind cells with certain cell surface antigens. These methods can be combined to yield a relatively pure population of hematopoietic stem cells for use in the present invention.
  • cell density gradients e.g., Ficoll-Paque
  • cell sorting using cell surface antigens e.g., with a fluorescence activated cell sorter
  • magnetic beads StemSep Technologies
  • Ficoll Paque method and the magnetic bead method can be combined to yield hematopoietic stem cells with a purity of greater than about 85% and optimally of about 99% purity.
  • Hematopoietic stem cells can also be isolated from peripheral blood using similar techniques. See Care et al, 1999); Janowski-Wieczorek et al, 1999.
  • the stem cell of the present method is preferably isolated from a mammal. More preferably, the mammal is a human. It is well understood in the art that studies using hematopoietic stem cells of avian or murine origin are applicable to human studies. In clinical studies, especially in the field of hematology, the mouse is the preferred system when human donors are unavailable. Thus, it is understood by those skilled in the art that methods of using avian and murine hematopoietic stem cells can be readily adapted to uses involving human hematopoietic stem cells.
  • the step of contacting stem cells with a growth factor or a combination of growth factors is preferably in vitro.
  • the stem cell is isolated, cultured, and contacted in vitro with a growth factor or combination of growth factors.
  • the culture conditions can include a semisolid culture medium, but is not limited to that type of culture.
  • growth factor is meant an agent that, at least, promotes cell growth or induces phenotypic changes.
  • the growth factor or combination of growth factors of the present invention at least induces proliferation of hematopoietic stem cells or induces hematopoietic stem cells to differentiate into cardiomyocytes.
  • the growth factor or combination of growth factors used in the present method of differentiating cardiomyocytes is selected from the group consisting of retinoic acid, stem cell factor, basic fibroblast growth factor, acidic fibroblast growth factor, endothelial cell growth factor, fibroblast growth factor-4, endothelin-1, interleukin (including, e.g., IL-2, IL-10 and 11-15), transforming growth factor alpha (TGF ⁇ ), transforming growth factor beta (TGF ⁇ ), GM-CSF, IGF- 1 , platelet derived growth factor (PDGF), bone morphogenic factor-4, and Wnt (e.g., a member of the class Wnt5a, including e.g.,Wntl 1 ).
  • the hematopoietic stem can be contacted with dexamethasone, hyaluronic acid, 3,3',5-triiodo-L-thyronine, cAMP, angiotensin II, mannose, ⁇ -mercaptoethanol, and/or a Protein Kinase C (PKC) inhibitor (including, e.g., sphingosine) to optimize cardiomyocyte differentiation.
  • Endothelial cell growth factor comprises acidic fibroblast growth factor and heparin.
  • endothelial cell growth factor or acidic fibroblast growth factor can be used interchangeably in the invention.
  • the combination of growth factors used in the present method of differentiating cardiomyocytes will comprise retinoic acid, basic fibroblast growth factor, fibroblast growth factor-4, Wnt (e.g., a member of the class Wnt5a, including e.g.,Wntl 1 ), bone morphogenic protein-4, and either acidic fibroblast growth factor or endothelial cell growth factor.
  • Wnt e.g., a member of the class Wnt5a, including e.g.,Wntl 1
  • the hematopoietic stem can be additionally contacted with dexamethasone to optimize cardiomyocyte differentiation.
  • the growth factor or combination of growth factors of the present invention at least induces proliferation of hematopoietic stem cells or induces hematopoietic stem cells to differentiate into skeletal muscle cells.
  • the growth factor or combination of growth factors used in the present method of differentiating skeletal muscle cells is selected from the group consisting of retinoic acid, basic fibroblast growth factor, interleukin (e.g., IL-2 and/or IL-15), stem cell factor, IGF-1, endothelial cell growth factor, platelet derived growth factor, angiotensin II, TGF ⁇ , and endothelin.
  • the hematopoietic stem can be contacted with dexamethasone, 3,3',5-triiodo-L-thyronine, cAMP, ⁇ -mercaptoethanol, and/or hyaluronic acid to optimize skeletal muscle cell differentiation.
  • the combination of growth factors used in the present method of differentiating skeletal muscle cells will comprise basic fibroblast growth factor, SCF, TGF- ⁇ (preferably, TGF- ⁇ 1), and endothelin.
  • a further inducing step of the present method can be used to induce the noncontracting cardiomyocytes derived from the stem cells to contract, wherein the inducement is by contacting the noncontracting cardiomyocytes with embryonic, fetal, or postnatal contracting cardiomyocytes; by changes in ion concentration (e.g., high K + ); by electrical or mechanical stimulation.
  • the step of contacting either the cardiomyocytes, derived from the stem cells can take place in vivo (e.g., by transplantation) or in vitro.
  • the preferred concentration of retinoic acid in the culture medium as used in the present invention is between 1X10 "6 and 1X10 "10 M. More preferably the concentration is between 1X10 7 and 1X10 "9 M. Even more preferably, the concentration of retinoic acid is 2X10 "8 M.
  • the preferred concentration of stem cell factor in the culture medium as used in the present invention is between 5 and 200 ng/ml. More preferably, the concentration is between 50 and 150 ng/ml. Even more preferably, the concentration is lOOng/ml.
  • the preferred concentration of basic fibroblast growth factor in the culture medium as used in the present invention is between 10 and 300 ng/ml. More preferably, the concentration is between 25 and 250 ng/ml. Even more preferably, the concentration is lOOng/ml.
  • the preferred concentration of acidic fibroblast growth factor in the culture medium as used in the present invention is between 10 and 300 ng/ml. More preferably, the concentration is between 25 and 250 ng/ml. Even more preferably, the concentration is lOOng/ml.
  • the preferred concentration of endothelial cell growth factor in the culture medium as used in the present invention is between 0.1 and 1000 ⁇ g/ml. More preferably, the concentration is between 1 and 100 ⁇ g/ml. Even more preferably, the concentration is 5 ⁇ g/ml for the differentiation into cardiomyocytes, and 100 ⁇ g/ml for the differentiation into skeletal muscle cells.
  • the preferred concentration of fibroblast growth factor-4 in the culture medium as used in the present invention is between 10 and 300 ng/ml. More preferably, the concentration is between 25 and 200 ng/ml. Even more preferably, the concentration is lOOng/ml.
  • the preferred concentration of endothelin-1 in the culture medium as used in the present invention is between 1X10 "5 and 1X10 "11 M. More preferably the concentration is between 1X10 "6 and 1X10 "10 M. Even more preferably, the concentration is 1X10 "7 M.
  • the transforming growth factor- ⁇ of the present invention includes transforming growth factor- ⁇ 1, transforming growth factor- ⁇ 2, and transforming growth factor- ⁇ 3.
  • the preferred concentration of transforming growth factor- ⁇ 1, - ⁇ 2, or - ⁇ 3 in the culture medium as used in the present invention is between 0.1 and 100 ng/ml. More preferably, the concentration is between 1 and 50 ng/ml. Even more preferably, the concentration is lOng/ml.
  • the preferred concentration of interleukin in the culture medium of the present invention is between 1 and 500 ng/ml.
  • the preferred concentration of IL-10 is 25-75 ng/ml. Even more preferably, the concentration of IL-10 is 50 ng/ml.
  • the preferred concentrations of IL-2 and IL-15 are 1-20 ng/ml, and, more preferably, 10 ng/ml.
  • the preferred concentration of transforming growth factor alpha (TGF ⁇ ) in the culture medium of the present invention is between 0.5 and 50 ng/ml. More preferably the concentration is between 1 and 10 ng/ml, and, even more preferably, the concentration is 5 ng/ml.
  • the culture medium can comprise about 5-80% Wnt conditioned medium.
  • the culture medium comprises about 25-60% Wnt conditioned medium. Even more preferably, the culture medium comprises about 50% Wnt conditioned medium.
  • the preferred concentration of dexamethasone in the culture medium of the present invention is between 5 X 10 "6 and 5 X 10 "12 . More preferably, the concentration is between 1 X 10 7 and 1 X 10 "10 , and, even more preferably, the concentration is 5 X 10- 7 .
  • the preferred concentration for a PKC inhibitor in the culture medium of the present invention is between 2.5 X 10 "6 and 2.5 X 10 "12 M.
  • the concentration will vary depending on the PKC inhibitor that is used.
  • the preferred concentration of sphingosine is between 1 X 10" 7 M and 5 X 10 "7 M, and more preferably is 2.5 X 10 "
  • the preferred concentration of platelet derived growth factor in the culture medium of the present invention is between 0.1 ng/ml andlOO ng/ml.
  • the more preferred concentration is lng/ml to 20 ng/ml. Even more preferably, the concentration is lOng/ml.
  • the preferred concentration of 3,3',5-triiodo-L-thyronine in the culture medium as used in the present invention is 2 ng/ml to 500 ng/ml. More preferably, the concentration is 10-100 ng/ml, and even more preferably the concentration is 20 ng/ml as used in promoting differentiation of cardiomyocytes, and 50 ng/ml as used in promoting differentiation of skeletal muscle cells.
  • the preferred concentration of cAMP in the culture medium as used in the present invention is 5 X 10 "5 M to 5 X 10 "3 M. More preferably, the concentration is 1 X 10 "4 M to 1 X 10 " M, and even more preferably the concentration is 5 X 10 "4 M.
  • the preferred concentration of angiotensin II in the culture medium as used in the present invention is 1 X 10 "8 to 1 X 10 "6 . More preferably, the concentration is 1 X 10 "7 M.
  • the preferred concentration of hyaluronic acid in the culture medium as used in the present invention is 10 ⁇ g/ml to 1000 ⁇ g/ml. More preferably, the concentration is 50 ⁇ g/ml to 500 ⁇ g/ml, and even more preferably the concentration is 100 ⁇ g/ml.
  • the preferred concentration of 2-ME ( ⁇ -mercaptoethanol) in the culture medium as used in the present invention is 5 ⁇ M to 500 ⁇ M. More preferably, the concentration is 25 ⁇ M to 100 ⁇ M, and even more preferably the concentration is 50 ⁇ M .
  • the preferred concentration of GM-CSF in the culture medium as used in the present invention is 1 ng/ml to 1000 ng/ml. More preferably, the concentration is 50 ng/ml to 200 ng/ml, and even more preferably the concentration is 100 ng/ml.
  • the preferred concentration of IGF-1 in the culture medium as used in the present invention is 5 ng/ml to 500 ng/ml. More preferably, the concentration is 25 ng/ml to 100 ng/ml, and even more preferably the concentration is 50 ng/ml.
  • the preferred concentration of mannose in the culture medium as used in the present invention is 50 ⁇ g/ml to 5000 ⁇ g/ml. More preferably, the concentration is 250 ⁇ g/ml to 1000 ⁇ g/ml, and even more preferably the concentration is 500 ⁇ g/ml.
  • the preferred concentration of bone morphogenic factor-4 (or bone morphogenic protein-4 or BMP-4) in the culture medium as used in the present invention is 5 ng/ml to 500 ng/ml. More preferably, the concentration is 25 ng/ml to 100 ng/ml, and even more preferably the concentration is 50 ng/ml.
  • the culture medium used in the present invention preferably further comprises Iscove's Modified Delbecco's Medium, or the equivalent thereof, and 20% serum.
  • the serum is fetal bovine serum.
  • the present invention also provides a process of promoting differentiation of a hematopoietic stem cell into a cardiomyocyte or skeletal muscle cell, comprising the steps of obtaining a hematopoietic stem cell with cardiomyocyte or skeletal muscle cell potential from an embryonic donor or nonembryonic donor and contacting the hematopoietic stem cell with a growth factor or combination of growth factors, thereby promoting differentiation of the hematopoietic stem cell into the cardiomyocyte or skeletal muscle cell.
  • the hematopoietic stem cell can be contacted with cardiac tissue to promote differentiation of a hematopoietic stem cell into a cardiomyocyte or, alternatively, contacted with skeletal muscle to promote differentiation of a hematopoietic stem cell into a skeletal muscle cell.
  • Hematopoietic stem cells can be isolated from the aorta-gonad-mesonephros area, the liver, the spleen, the yolk sac, or the bone marrow of an embryonic donor or from the liver, spleen, or, more preferably, the blood or bone marrow of a donor.
  • the term "hematopoietic stem cell” does not include the totipotential embryonic stem cell.
  • the present invention also provides an enriched population of hematopoietic stem cells with cardiomyocyte or skeletal muscle cell potential, wherein the hematopoietic stem cells are derived from an embryo.
  • the present invention provides a further process of promoting differentiation of a stem cell into a cardiomyocyte or skeletal muscle cell, comprising the steps of obtaining a stem cell with cardiomyocyte with skeletal muscle cell potential from a nonembryonic donor or a hematopoietic stem cells from a embryonic donor and transfecting the cell with a nucleic acid sequence that promotes differentiation of the stem cell into the cardiomyocyte or skeletal muscle cell.
  • the transfecting step is performed using standard techniques well known in the art. (Molecular Cloning, eds. Sambrook, Fritsch, and Maniatis, 1989) .
  • nucleic acid sequences that promote differentiation of stem cells into cardiomyocytes include, among other, the cardiac Nk2-type homeobox genes (e.g., Nkx2.3, Nkx2.5, Nkx2.6, Nkx 2.7, Nkx2.8 and Nkx2.9) (Patterson et al., 1998), its vertebrate ancestral gene tinman (Bodmer, 1993); GATA-4, GATA-5 and GATA-6 (Jiang et al., 1998), or serum response factor (SRF; Chen Swartz, 1996).
  • cardiac Nk2-type homeobox genes e.g., Nkx2.3, Nkx2.5, Nkx2.6, Nkx 2.7, Nkx2.8 and Nkx2.9
  • the cardiac Nk2-type homeobox genes e.g., Nkx2.3, Nkx2.5, Nkx2.6, Nkx 2.7, Nkx2.8 and Nkx2.9
  • SRF serum response factor
  • the present invention provides a further process of promoting differentiation of a hematopoietic stem cell into a cardiomyocyte or skeletal muscle cell, comprising the steps of obtaining a hematopoietic stem cell with cardiomyocyte or skeletal muscle cell potential from an embryonic or nonembryonic donor and inducing the hematopoietic stem cells to differentiate into a contracting cardiomyocyte or skeletal muscle cell.
  • the hematopoietic stem cell is induced to differentiate into a cardiomyocyte or skeletal muscle cell and further induced to become a contracting cardiomyocyte or skeletal muscle cell in vivo without the step of transfecting the hematopoietic stem cell.
  • the induction step of promoting contraction is without contacting the differentiated cardiomyocyte or skeletal muscle cell with a growth factor or combination of growth factors.
  • cardiomyocytes or skeletal muscle cells derived by the process of the invention.
  • the cardiomyocytes and skeletal muscle cells of the invention can be readily identified by their expression of at least one characteristic of a cardiomyocyte or a skeletal muscle cell, respectively.
  • the cardiomyocytes of the present invention are non-contracting but are capable of contraction upon inducement.
  • the skeletal muscle cells are non-twitching but are capable of twitching upon inducement.
  • the cardiomyocytes or skeletal muscle cells of the present invention can be used in a variety of methods, such as transplantation.
  • the cardiomyocytes or skeletal muscle cell can be used to screen pharmacological agents for their effect on cardiac or skeletal muscle activity, comprising contacting a cardiomyocyte or skeletal muscle cell of the present invention with the compound and determining the effect of the compound on the activity of the cardiomyocyte or skeletal muscle cell.
  • the present method further provides a method of screening for a compound that promotes cardiac or skeletal muscle activity comprising stimulating the cardiomyocytes or skeletal muscle cells to contract or twitch, contacting the cardiomyocytes or skeletal muscle cells of the present invention with the compound, and determining whether the compound promotes cardiac or skeletal muscle activity.
  • Effects on cardiac or skeletal muscle activity can be assessed using methods well known in the art, including, for example, assessing toxicity, protein expression or secretion, contractile strength or frequency, and ion channel fluctuations (e.g., voltage dependent and receptor mediated Ca ⁇ channel fluctuations).
  • ion channel fluctuations e.g., voltage dependent and receptor mediated Ca ⁇ channel fluctuations.
  • the cardiomyocytes or skeletal muscle cells could also be used in an implantable artificial heart or ventricular assist device, for example, as the myocardial layer.
  • the cardiomyocytes or skeletal muscle cell can be used as the myocardial layer in a tissue-engineered heart or ventricular assist device.
  • the cardiomyocytes and the skeletal muscle cells could be used also as a food source (including, for example, a source of protein for animal feed).
  • the present invention also provides a relatively pure population of stem cells with cardiomyocyte or skeletal muscle cell potential, wherein the stem cells are derived from a nonembryonic donor. Also provided is a relatively pure population of hematopoietic stem cells with cardiomyocyte or skeletal muscle cell potential, wherein the stem cells are derived from a nonembryonic or an embryonic donor.
  • “relatively pure population” is meant a population of cells comprising at least about 80% stem cells with cardiomyocyte or skeletal muscle cell potential. More preferably, the population comprises at least about 90% stem cells with cardiomyocyte or skeletal muscle cell potential. Even more preferably, the population comprises at least about 95% stem cells with cardiomyocyte or skeletal muscle cell potential. Most preferably, the population comprises at least about 99% stem cells with cardiomyocyte or skeletal muscle cell potential.
  • the stem cells of the invention can be used in a variety of methods, such as transplantation. Also, the stem cells can be used in a method of identifying nucleic acids with cardiomyocyte or skeletal muscle cell differentiation promoting activity, comprising transfecting a nucleic acid of unknown cardiac or skeletal muscle cell differentiation promoting activity into the stem cell of the invention, culturing the transfected cells, and determining the presence of differentiated cells having one or more characteristics of cardiomyocytes or skeletal muscle cells.
  • the present invention also provides a composition, comprising stem cells with cardiomyocyte potential derived from a nonembryonic donor and retinoic acid, stem cell factor, basic fibroblast growth factor, acidic fibroblast growth factor, endothelial cell growth factor, fibroblast growth factor-4, endothelin-1, interleukin (including, e.g., IL-2, IL-10 and 11-15), transforming growth factor alpha (TGF ⁇ ), transforming growth factor beta (TGF ⁇ ), GM-CSF, IGF-1, platelet derived growth factor (PDGF), bone morphogenic factor-4, and Wnt (e.g., a member of the class Wnt5a, including e.g.,Wntl 1 ).
  • TGF ⁇ transforming growth factor alpha
  • TGF ⁇ transforming growth factor beta
  • GM-CSF GM-CSF
  • IGF-1 platelet derived growth factor
  • PDGF platelet derived growth factor
  • bone morphogenic factor-4 and Wnt (e
  • composition can further comprise dexamethasone, hyaluronic acid, 3,3',5-triiodo-L-thyronine, cAMP, angiotensin II, mannose, ⁇ - mercaptoethanol, and/or a Protein Kinase C (PKC) inhibitor (including, e.g., sphingosine).
  • PKC Protein Kinase C
  • the composition comprises stem cells with cardiomyocyte potential derived from a nonembryonic donor and retinoic acid, basic fibroblast growth factor, fibroblast growth factor-4, Wnt (e.g., a member of the class Wnt5a, including e.g.,Wntl 1 ), bone morphogenic protein-4, dexamethasone, and either acidic fibroblast growth factor or endothelial cell growth factor.
  • Wnt e.g., a member of the class Wnt5a, including e.g.,Wntl 1
  • Wnt e.g., a member of the class Wnt5a, including e.g.,Wntl 1
  • dexamethasone e.g., dexamethasone
  • the composition comprises stem cells with cardiomyocyte potential derived from a nonembryonic donor and retinoic acid, stem cell factor, fibroblast growth factor-4, endothelin-1, transforming growth factor beta, and either basic fibroblast growth factor or endothelial cell growth factor in amounts to promote the differentiation of the stem cells into cardiomyocytes.
  • the composition can alternatively comprise the stem cells and two or more of the factors, including, e.g., stem cells with cardiomyocyte potential derived from a nonembryonic donor, and retinoic acid and stem cell factor, retinoic acid and fibroblast growth factor-4, retinoic acid and endothelin-1, retinoic acid and transforming growth factor beta, retinoic acid and either basic fibroblast growth factor or endothelial cell growth factor, stem cell factor and fibroblast growth factor-4, stem cell factor and endothelin-1, stem cell factor and transforming growth factor beta, stem cell factor and either basic fibroblast growth factor or endothelial cell growth factor, fibroblast growth factor-4 and endothelin-1, fibroblast growth factor-4 and transforming growth factor beta, fibroblast growth factor- 4 and either basic fibroblast growth factor or endothelial cell growth factor, transforming growth factor beta and either basic fibroblast growth factor or endothelial cell growth factor, or stem cell factor and fibroblast growth factor-4
  • the stem cells are bone marrow or blood cells and, more preferably, hematopoietic stem cells, and, even more preferably, myeloid-lymphoid stem cells.
  • the stem cells are preferably isolated from a donor that is a mammal and, more preferably, a human.
  • the present invention also provides a composition, comprising hematopoietic stem cells with cardiomyocyte potential derived from an embryonic or nonembryonic donor and retinoic acid, stem cell factor, basic fibroblast growth factor, acidic fibroblast growth factor, endothelial cell growth factor, fibroblast growth factor-4, endothelin-1, interleukin (including, e.g., IL-2, IL-10 and 11-15), transforming growth factor alpha (TGF ⁇ ), transforming growth factor beta (TGF ⁇ ), GM-CSF, IGF- 1 , platelet derived growth factor (PDGF), bone morphogenic factor-4, and Wnt (e.g., a member of the class Wnt5a, including e.g.,Wntl 1 ).
  • composition can further comprise dexamethasone, hyaluronic acid, 3,3',5-triiodo-L-thyronine, cAMP, angiotensin II, mannose, ⁇ -mercaptoethanol, and or a Protein Kinase C (PKC) inhibitor (including, e.g., sphingosine).
  • PKC Protein Kinase C
  • the composition comprises hematopoietic stem cells with cardiomyocyte potential derived from an embryonic or nonembryonic donor and retinoic acid, basic fibroblast growth factor, fibroblast growth factor-4, Wnt (e.g., a member of the class Wnt5a, including e.g.,Wntl 1 ), bone morphogenic protein-4, dexamethasone, and either acidic fibroblast growth factor or endothelial cell growth factor.
  • Wnt e.g., a member of the class Wnt5a, including e.g.,Wntl 1
  • Wnt a member of the class Wnt5a, including e.g.,Wntl 1
  • dexamethasone dexamethasone
  • the composition comprises hematopoietic stem cells with cardiomyocyte potential derived from an embryonic or nonembryonic donor and retinoic acid, stem cell factor, fibroblast growth factor-4, endothelin-1, transforming growth factor beta, and either basic fibroblast growth factor or endothelial cell growth factor.
  • the composition can alternatively comprise the hematopoietic stem cells and any combination of two or more of the factors, including, e.g., stem cells with cardiomyocyte potential derived from a nonembryonic donor, and retinoic acid and stem cell factor, retinoic acid and fibroblast growth factor-4, retinoic acid and endothelin-1, retinoic acid and transforming growth factor beta, retinoic acid and either basic fibroblast growth factor or endothelial cell growth factor, stem cell factor and fibroblast growth factor-4, stem cell factor and endothelin-1, stem cell factor and transforming growth factor beta, stem cell factor and either basic fibroblast growth factor or endothelial cell growth factor, fibroblast growth factor-4 and endothelin-1, fibroblast growth factor-4 and transforming growth factor beta, fibroblast growth factor- 4 and either basic fibroblast growth factor or endothelial cell growth factor, transforming growth factor beta and either basic fibroblast growth factor or endothelial cell growth factor,
  • the present invention also provides a composition, comprising stem cells with skeletal muscle cell potential derived from a nonembryonic donor and retinoic acid, basic fibroblast growth factor, interleukin (e.g., IL-2 and/or IL-15), stem cell factor, IGF-1, endothelial cell growth factor, platelet derived growth factor, angiotensin II, TGF ⁇ , and endothelin-1.
  • the composition can further comprise dexamethasone, 3,3',5-triiodo-L-thyronine, cAMP, ⁇ -mercaptoethanol, and hyaluronic acid.
  • the composition comprises the stem cells with skeletal muscle cell potential derived from a nonembryonic donor and basic fibroblast growth factor, SCF, TGF- ⁇ (preferably, TGF- ⁇ 1), and endothelin.
  • the composition can alternatively comprise the stem cells and any combination of two or more of the factors in amounts to promote the differentiation of the stem cells into skeletal muscle cells, including, e.g., retinoic acid and basic fibroblast growth factor, retinoic acid and interleukin, retinoic acid and PDGF, retinoic acid and angiotensin, retinoic acid and TGF ⁇ , retinoic acid and endothelin, basic FGF and interleukin, basic FGF and SCF, basic FGF and IGF- 1 , basic FGF and ECGF, basic FGF and PDGF, basic FGF and angiotensin II, basic FGF and TGF ⁇ , basic FGF and endothelin-1, SCF and interleukin, SCF and IGF-1,
  • the stem cells are bone marrow or blood cells and, more preferably, hematopoietic stem cells, and, even more preferably, myeloid-lymphoid stem cells.
  • the stem cells are preferably isolated from a donor that is a mammal and, more preferably, a human.
  • the present invention also provides a composition, comprising hematopoietic stem cells with skeletal muscle potential derived from an embryonic or nonembryonic donor and retinoic acid, basic fibroblast growth factor, interleukin (e.g., IL-2 and/or IL- 15), stem cell factor, IGF-1, endothelial cell growth factor, platelet derived growth factor, angiotensin II, TGF ⁇ , and endothelin-1.
  • the composition can further comprise dexamethasone, 3,3',5-triiodo-L-thyronine, cAMP, ⁇ -mercaptoethanol, and hyaluronic acid.
  • the composition comprises hematopoietic stem cells with skeletal muscle potential derived from an embryonic or nonembryonic donor and basic fibroblast growth factor, SCF, TGF- ⁇ (preferably, TGF- ⁇ 1), and endothelin.
  • the composition can alternatively comprise the hematopoietic stem cells and any combination of two or more of the factors in amounts to promote the differentiation of the hematopoietic stem cells into skeletal muscle cells, including, e.g., retinoic acid and basic fibroblast growth factor, retinoic acid and interleukin, retinoic acid and PDGF, retinoic acid and angiotensin, retinoic acid and TGF ⁇ , retinoic acid and endothelin, basic FGF and interleukin, basic FGF and SCF, basic FGF and IGF-1, basic FGF and ECGF, basic FGF and PDGF, basic FGF and angiotensin II, basic FGF and TGF ⁇ , basic FGF and endothelin-1, SCF and interleukin, SCF and IGF-1, SCF and ECGF, SCF and PDGF, SCF and angiotensin II, SCF and TGF ⁇ , SCF and endothelin-1, SCF and
  • the present invention also provides a method of determining whether nonembryonic stem cells or embryonic hematopoietic stem cells of unknown cardiomyocyte or skeletal muscle potential can be promoted to differentiate into cardiomyocytes or skeletal muscle, comprising the steps of contacting the stem cells with a growth factor or combination of growth factors under conditions that allow the cells to differentiate, and determining the presence of differentiated cells having one or more characteristics of cardiomyocytes or skeletal muscle cells.
  • the contacting step preferably occurs in vitro.
  • the stem cells can be cultured in semisolid or other type of culture medium.
  • the cells can be allowed to differentiate in culture and screened for expression of cardiomyocyte- or skeletal muscle cell- specific proteins to determine whether the cells become cardiomyocytes or skeletal muscle cells.
  • the growth factor or combination of growth factors is selected from the group consisting of retinoic acid, stem cell factor, basic fibroblast growth factor, acidic fibroblast growth factor, endothelial cell growth factor, fibroblast growth factor-4, endothelin-1, interleukin (including, e.g., IL-2, IL-10 and 11-15), transforming growth factor alpha (TGF ⁇ ), transforming growth factor beta (TGF ⁇ ), GM-CSF, IGF-1, platelet derived growth factor (PDGF), bone morphogenic factor-4, and Wnt (e.g., a member of the class Wnt5a, including e.g.,Wntl 1 ).
  • interleukin including, e.g., IL-2, IL-10 and 11-15
  • TGF ⁇ transforming growth factor alpha
  • TGF ⁇ transforming growth factor beta
  • GM-CSF GM-CSF
  • IGF-1 platelet derived growth factor
  • PDGF platelet derived growth factor
  • the cell to be screen can be further contacted with dexamethasone, hyaluronic acid, 3,3',5-triiodo-L-thyronine, cAMP, angiotensin II, mannose, ⁇ -mercaptoethanol, and/or a Protein Kinase C (PKC) inhibitor (including, e.g., sphingosine).
  • PKC Protein Kinase C
  • the combination of growth factors used in the present screening method will comprise retinoic acid, basic fibroblast growth factor, fibroblast growth factor-4, Wnt (e.g., a member of the class Wnt5a, including e.g.,Wntl 1 ), bone morphogenic protein-4, and either acidic fibroblast growth factor or endothelial cell growth factor.
  • Wnt e.g., a member of the class Wnt5a, including e.g.,Wntl 1
  • the cell to be screened can be additionally contacted with dexamethasone.
  • the growth factor or combination of growth factors is selected from the group consisting of retinoic acid, basic fibroblast growth factor, interleukin (e.g., IL-2 and or IL-15), stem cell factor, IGF-1, endothelial cell growth factor, platelet derived growth factor, angiotensin II, TGF ⁇ , and endothelin.
  • the cell to be screened can be further contacted with dexamethasone, 3,3',5-triiodo-L-thyronine, cAMP, ⁇ -mercaptoethanol, and/or hyaluronic acid.
  • the cell to be screened will be contacted with basic fibroblast growth factor, SCF, TGF- ⁇ (preferably, TGF- ⁇ 1), and endothelin.
  • SCF basic fibroblast growth factor
  • TGF- ⁇ preferably, TGF- ⁇ 1
  • endothelin endothelin.
  • the invention also provides a method of treating a subject with heart injury or disease, comprising transplanting the cardiomyocytes of the present invention, or alternatively the stem cells with cardiomyocyte potential, into the cardiac muscle of the subject, thereby improving cardiac function.
  • the invention also provides a method of treating a subject with a muscle injury or disease, comprising transplanting the skeletal muscle cells of the present invention, or alternatively the stem cells with skeletal muscle potential, into the skeletal muscle of the subject, thereby improving muscle function.
  • the subject can be an embryo, a fetus, or a postnatal subject.
  • the cardiomyocytes, skeletal muscle cells, or stem cells are transfected prior to transplantation with a nucleic acid.
  • the nucleic acid can comprise a nonmutated gene, wherein the subject being treated has a mutated gene.
  • the stem cells are preferably bone marrow or blood cells, and, more preferably, hematopoietic stem cells, and even more preferably, myeloid-lymphoid stem cells.
  • the cardiomyocytes or skeletal muscle cells of the present invention are transplanted.
  • the stem cells of the present invention can be transplanted directly into cardiac or skeletal muscle tissue and be allowed to differentiate into cardiomyocytes or skeletal muscle cells. Using the treatment method of the invention, the transplanted cardiomyocytes, skeletal muscle cells, or stem cells, can become integrated into the cardiac or skeletal muscle of the subject being treated.
  • the donor of the stem cells is also the subject being treated, thereby avoiding the need for chronic immunosuppression therapy.
  • the donor of the stem cells can be the mother of the developing embryonic or fetal subject.
  • the subject being treated is a mammal and, more preferably, a human. Improvement in cardiac or skeletal muscle function of a subject following transplantation can be determined using a variety of clinical methods well known to those skilled in the art, including, for example, measuring cardiac output, blood pressure, and heart rate for improved cardiac function and increased contractility or strength for skeletal muscle function.
  • bone marrow stem cells possess the potential to manifest a cardiac phenotype
  • bone marrow cultures were established from the femurs of ED 16 chicken or ED14 quail embryos as previously described (Coll and Ingram, 1978; Cormier and Dieterlen-Lievre, 1990; Nicolas-Bolnet et al, 1995). Bone marrow cells were segregated into distinct hematopoietic stem cell (HSC) and stromal cell populations following Ficoll-Paque separation and adhesion selection (Metcalf, 1984; Petzer et al., 1996).
  • HSC hematopoietic stem cell
  • retinoic acid (2X10" 8 )
  • stem cell factor 100 ng/ml
  • bFGF lOOng/ml
  • FGF-4 lOOng/ml
  • endothelin-1 (1X10 "7 )
  • TGF ⁇ 10 ng/ml
  • Endothelial cell growth factor 5 ⁇ g/ml
  • Either TGF ⁇ -1, -2, or -3 can be used.
  • stromal cell cultures did not exhibit any cells that demonstrated a phenotype typical of early mesoderm.
  • bone marrow cells that exhibited an early mesodermal phenotype were found among the HSC population.
  • these cells were incorporated into the avian blastoderm suspension cultures previously described (Eisenberg and Markwald, 1997).
  • either chicken or quail HSCs were labeled with a vital dye prior to mixing with blastoderm cells from HH stage 5 chicken or quail embryos. The results were quite exciting. Some of the HSCs were found incorporated into areas that demonstrated contraction prior to immunohistochemical staining. These cells were found to be sarcomeric myosin-positive, as were the blastoderm cells associated with them.
  • bone marrow/blastoderm cell suspensions were plated at high micromass cell densities into 8- well Lab-Tek chamber slides. Following 4 days in culture, cells were stained with 109- 19 antibody which specifically binds to cardiomyocytes. These bone marrow cells displayed myofibrils of cardiac-specific sarcomeric myosin. Additionally, these experiments were performed in parallel using bone marrow stromal cells. When mixed with HH stage 5 blastoderm cells, stromal cells did display a skeletal muscle phenotype. However, no cardiac phenotype, as determined by contractility and cardiac-specific protein expression, was observed in these stromal cell containing cultures.
  • bone marrow cells were harvested from adult mice, Ficoll-Paque and adhesion separated, and cultured in conditions that stimulate cardiac differentiation in vitro.
  • Adult CDl or C57 male mice were sacrificed and the limbs removed.
  • the bones of each limb were placed in ⁇ MEM + P/S cell medium.
  • the bones were cleaned of as much excess tissue as possible, then the tips of the bones were removed so that the bone marrow could be easily removed.
  • the bone marrow was harvested from the bone by flushing the bone marrow out of the bone with a stream of cell medium from a 26G needle on a 1 cc syringe.
  • the cells were pipetted into bacterial grade (nonadhering) petri dishes containing ⁇ MEM cell medium.
  • the cords of bone marrow were flushed apart by drawing the tissue up into a lOcc syringe with a 20G needle. Residual cells were washed from the surface of the plate and drawn into the lOcc syringe.
  • the resulting cell suspension was run through a sterile sieve (70 ⁇ m) into a 50ml conical tube to remove any large pieces of bone that remain.
  • Ten-twenty ml of cell medium was run through the sieve to wash any remaining cells off of the sieve and into the centrifuge tube.
  • the cells were spun in a centrifuge at 1,000RPM for 10 min.
  • the cells were resuspended in lml ⁇ MEM and a cell count, using the vital dye 4% trypan blue, with a hemocytometer (counting chamber), yielding the total number of cells extracted from the bone marrow.
  • the cell sample was diluted to 5X10 6 cells/ml, and 4ml of the diluted cells was layered atop 3ml of Ficoll/Paque, according to the manufacturer's instructions, in a 15ml conical centrifuge tube. The tubes were placed in the centrifuge and spun for 30min at 1,350 RPM. Subsequently, the band of leukocytes (i.e., the buffy coat) is harvested at the Ficoll/Pacque- ⁇ MEM interface.
  • the band of leukocytes i.e., the buffy coat
  • the resulting cells were diluted in lml ⁇ MEM and counted.
  • the cells were diluted to 1X10 6 cells/ml in ⁇ MEM containing 10% FBS and placed in a tissue culture dish (35mm, 60mm, or 100mm using 2ml, 5ml, or 10ml of cells, respectively).
  • the cultured cells were incubated overnight at 5% CO 2 and 37°C for adherence depletion.
  • the nonadherent cells were subsequently removed from each dish with a pipette and placed in a 15ml conical centrifuge tube. The dish was gently rinsed with ⁇ MEM without serum to remove any remaining nonadherent cells and to remove serum from the dish, as serum interferes with the activity of trypsin.
  • the cells were added to the tube of nonadherent cells.
  • the adherent cells were loosened with trypsin-EDTA for approximately 10 min at 37°C.
  • the adherent cells were removed as thoroughly as possible by gently pipetting and rapping the dishes against a hard surface, and the adherent cells were placed in centrifuge tubes.
  • the tubes of adherent cells and the tubes of nonadherent cells were centrifuged for 10 min.
  • the adherent and nonadherent cells were then resuspended in lml of ⁇ MEM cell medium and counted.
  • a portion of the isolated cells were then plated in a semisolid culture medium.
  • the tubes were then mixed by inversion, end over end, until the cultures were homogeneous.
  • the semisolid culture was then drawn up into a 3cc syringe with a 16G needle, and squirted into tissue culture suspension dishes (35mm). Pairs of the suspension dishes were placed in a 20X100mm tissue culture dish, along with a 35mm dish filled with distilled water (to prevent the gels from drying out).
  • the dishes were then placed in an incubator at 5% CO 2 and 37°C and incubated for 4-10 days and markers for HSCs were used to verify that the cells were HSCs.
  • stromal cell- and HSC-derived cultures contained cells that exhibited sarcomeric protein expression, but only HSC-derived cells, in small numbers, exhibited reactivity to cardiac specific myosin antibodies.
  • the cell populations were stained for the skeletal muscle-specific transcription factor MyoD. (Molkentin and Olson, 1996). Only stromal cells showed nuclear MyoD staining. These results indicate that sarcomeric protein expression of the HSC-enriched cells is indicative of cardiac muscle cells. The percentage of cells within the isolated cultures of mammalian, nonadherent cells that manifested cardiac phenotype was 0.01%, as compared to 0.02% in avian cultures. The abundance of HSCs in adult mammals represents up to 0.05% of the cell population within bone marrow (Morrison et al, 1995). These results, therefore, suggest that the cells with cardiomyocyte potential represent a subpopulation of the HSCs.
  • Multipotent stem cells can be separated from lineage-committed progenitors based on their Lin” phenotype.
  • Lin designates the absence of lineage markers B220 (all pre-B and B cells), Gr-1 (granulocytes), Mac-1 (myelomonocytic cells) and CD4 and CD8 (T cells) (Spangrude et al, 1988).
  • a highly enriched population of Lin " multipotent stem cells can be obtained from the bone marrow using the murine-specific StemSep kit (StemCell Technologies, Inc.). Unlike Dynabeads, this is a negative selection technique where the cells of interest are purified from remaining unwanted cells targeted for removal by monoclonal antibodies and magnetic colloid. This method is very effective for instances when the desired cell type is rare.
  • a cocktail of monoclonal antibodies specific for the lineage markers has proven successful
  • the starting bone marrow cell suspension does not need to be subjected to Ficoll-Paque or adherence depletion.
  • An antibody cocktail is simply added to the cell suspension followed by the addition of the magnetic colloid.
  • the cell suspension is then passed through a magnetic column which binds the unwanted cells. Desired cells are collected in the flow through volume, ready to use.
  • cell specific antibodies e.g., Gr-1 in conjunction with Dynabeads or CELLection Positive Isolation System (Dynal) can be used to positively select the HSC subpopulation to be tested.
  • the CELLection Positive Isolation System reagent consists of superparamagnetic microspheres to which biotintylated antibodies are attached via a cleavable linker. Thus, the desired population is purified by magnetic separation and subsequently released from the particles for further experimentation.
  • Antibodies to be used include CD33 antibody for harvesting myeloid progenitors and CD9, CD 10, and B220 for pre-B cells.
  • the cells isolated by either the StemSep or CELLection procedures can be cultured as described in the previous Examples to stimulate cardiac differentiation and assayed for cardiac protein expression.
  • the subpopulations of HSC cells can be added to individual wells of fibronectin-coated Lab-Tek chamber slides (Nunc, Naperville, IL) and treated for 48 hours with growth factor cocktail, as described above to stimulate cardiac differentiation of non-separated HSCs. The cultures can then be assayed for cardiac protein expression using immunohistochemistry.
  • the MF20 which recognizes all isoforms of sarcomeric myosin heavy chain, and the anti -murine cardiac specific myosin antibody 492-4A5, as well as the myosin light chain-2 (MLC-2a) atrial and ventricular (MLC-2v) antibodies, can be used to assay cultures for cardiac phenotypes (Gruber et al, 1996; Kubalak et al, 1994; O'Brien et al, 1993). The latter three antibodies recognize only cardiac tissue in mice. Thus, the cells with cardiomyocyte potential can be isolated.
  • HSCs cultured under various culture conditions known to stimulate specific lineages show that HSCs allowed to develop toward the myeloid-lymphoid stem cell intermediate retained the capacity to express muscle associated proteins.
  • monoDC cell clusters aggregates that represent a subset of cells restricted in lineage to monocytes, macrophages, and B, T, NK, and dendritic cells, were positive for sarcomeric myosin heavy chain following treatment with the growth factor cocktail that stimulates cardiac differentiation.
  • the cells with cardiac myocyte potential can be expanded according to the conditions as previously described (Yonemura et al, 1997).
  • Stem cells can be grown in medium containing ⁇ -MEM (GibcoBRL), 20% (vol/vol) fetal calf serum (Hyclone), 1% deionized Fraction V bovine serum albumin (StemCell Technologies, Inc.), 1 x 10 "4 mol/L 2-mercaptoethanol (Sigma), 100 ng/ml human recombinant FLT3/FLK-2 and 20 ng/ml human recombinant IL-II (both from PeproTech).
  • Cells can be cultured in 5% CO 2 /95% air within suspension dishes (Nunc) and fed fresh medium every 7 days for up to 21 days.
  • the rate of cell growth can be determined with a hemocytometer using trypan blue exclusion.
  • GEMM myeloerythroid
  • HSCs can be isolated as described above and plated in 35 mm suspension culture dishes (Nunc) containing - MEM (GibcoBRL), 1.2% (wt/vol) 1500 centipoise methylcellulose (StemCell Technologies, Inc.), 30% (vol/vol) fetal calf serum (Hyclone), 1% deionized Fraction V bovine serum albumin (StemCell Technologies, Inc.), 1 x 10 '4 mol/L 2-mercaptoethanol (Sigma), 5% (vol/vol) conditioned medium from pokeweed mitogen-stimulated spleen cells (PWM-SCCM; StemCell Technologies, Inc.), 100 ng/ml murine stem cell factor (SCF), 100 ng/ml human recombinant FLT3/FLK-2, 20 ng/ml human recombinant IL- II, 100 ng/ml murine IL-6, and 100 ng/ml human recombinant (G-CSF) gran
  • the primary colonies can then be individually lifted, washed in ⁇ -MEM and replated in the above conditions plus the addition of 100 ng/ml murine recombinant IL-3 (PeproTech) for 2 more days.
  • This method has been shown to promote the development of the GEMM progenitor while inhibiting the formation of the lymphocyte progenitors (Hirayama and Ogawa, 1996; Ogawa et al, 1997). Verification of both HSC and GEMM progenitor cell enrichment can be done by cytological examination with May- Grunwald Giemsa as well as antibody selection as described above.
  • the HSC expanded still retained that same phenotype, then these cells would pass through the StemSep column, yielding approximately the same number of cells as at the start of the selection. However, if during culture conditions these cells differentiated further down the hematopoietic lineage, they would be retained in this column, as demonstrated by a lower cell yield.
  • cells can be cultured as described in the previous Examples and assayed for cardiac specific protein expression.
  • the MF20, anti-murine cardiac specific myosin 492-4 A5, ⁇ -sarcomeric actin, cTnl, MLC-2a and MLC-2v antibodies can be used to assay cultures for cardiac phenotypes.
  • Control cultures can consist of mouse fetal cardiomyocytes and adherence depleted bone marrow cells. The latter cell population can produce cells with cardiac phenotypes following growth factor treatment. Additionally, the phenotype of expanded cell cultures in the absence of growth factors can be examined.
  • Both nonadherent bone marrow cells and the in vitro expanded cultures can be examined by either immunolabeling with antibodies such as the common leukocyte antigen CD45, CD 14 (monocyte) and the macrophage Mac-1 antigen CDl lb/18 (Roche Molecular Biochemicals, Indianapolis, IN) and staining with May-Grunwald Giemsa dyes to determine if blood cell differentiation was provoked.
  • the results of this phenotypic analysis guide further alterations in the expansion conditions in order to maintain the preferred stem cell state of the selected bone marrow cells. For example, if granulocytes were promoted by the in vitro expansion and this led to a noncardiogenic cell population, then G-CSF would be replaced in the chemically defined cocktail.
  • the ability of bone marrow-derived cardiomyocytes to function as normal cardiac tissue can be determined using the embryonic mouse ex ovo culture system. Furthermore, mouse embryos can be allowed to grow ex utero, to analyze the functional ability of the bone marrow-derived cells over a longer period of time.
  • retired breeder male rats can be anesthetized with Halothane (Henry Schein) prior to exposure of the inferior vena cava.
  • Halothane Halothane
  • Approximately 12 ml of blood is collected and immediately centrifuged at 3500 m for two 5 min spins.
  • the fibrin clot formed in the serum is squeezed with a sterile forceps to release the serum and the blood is then centrifuged again for 10 min.
  • the clear serum is pooled from all samples and centrifuged again for 10 min to removed residual blood cells.
  • the resulting serum is aliquoted together with 100 mg/ml streptomycin and 100 IU/ml penicillin into clean 50 ml conical tubes prior to storage at -20°C. Care is taken not to store the serum longer than 1 month.
  • the serum On the day of use, the serum is thawed at 37°C and heat inactivated at 56°C for 35 min.
  • Appropriate amount of Dulbecco's modified Eagle's medium (DMEM) can be added for a final volume of 3-4 ml of culture media per glass roller culture bottle.
  • Media filled bottles are placed in the rotating drum under continuous gassing for at least 1 hour prior to culture of embryos (this allows for the equilibration of media with gas).
  • the proportion of serum to media and the percentage O 2 is dependent upon the age of the embryo prior to culture. Younger embryos require a higher percentage serum, but less oxygen in the media, while the older embryos require less serum and more oxygen.
  • the decidual mass and Riechert's membrane are removed leaving the visceral yolk sac, the amnion, and the ectoplacental cone intact with embryos ED7.5-10.5 of age. Older embryos between ED10.5-11.5 are dissected further to pull away the visceral yolk sac and amnion from the embryo, leaving them attached so as to not disrupt the vessels connecting the embryo to the yolk sac or the umbilical vessels from the embryo to the placenta. Following microinjection of bone marrow-derived cells, embryos are transferred to the pre-equilibrated media in the roller culture bottles and incubated for the following 12-72 hours. The total time that the embryos are in culture depends both on the age of the embryo prior to culture (younger embryos can be cultured for a longer time than older ones) and on the desired time period for a particular experiment.
  • Multipotent HSC obtained from either ED14 quail bone marrow cells subjected to QH1 and/or 2G6 plus TAC1 selection or adult mouse bone marrow cells are enriched using StemSep and the Lin+ antibody cocktail.
  • PKH26-GL a vital dye PKH26-GL (Sigma) as described (Eisenberg and Markwald, 1997). Unlike Dil, this dye is not leaky for it becomes incorporated into the plasma membrane where it can remain stable for up to 100 days in culture. Bone marrow cells label quite well with this dye.
  • HSCs are injected using beveled-edged glass needles connected to a simple syringe mounted on a micromanipulator (World Precision Instruments).
  • microinjection volumes range from 0.5-4.0 ⁇ l. Lower volume amounts are used with younger embryos because of their fragility. Only a limited number of cells (1-12) can be transplanted directly into embryonic heart tissue. However, as many as 50 cells can be injected if delivery is through the yolk sac vessel. All micro injections are done with the aid of a dissecting microscope.
  • Cardiac phenotype can also be assessed after a longer period of time beyond that obtainable in ex ovo embryo cultures by using microinjections of embryos left ex utero. These experiments allow following the potential of these cells up until birth and beyond if desired. As with the ex ovo studies, all mice can be of the same allelic background, thus avoiding graft rejection. Because these cells can be in the embryo for a longer period of time, the cells are retrovirally labeled prior to transplantation. HSCs are easily transfected with retrovirus (Nienhuis et al., 1997; Sekhar et al, 1996). Specifically, the transfected cell contains both the bacterial ⁇ -galactosidase gene and green fluorescent protein (GFP).
  • GFP green fluorescent protein
  • Exo utero culture of mouse embryos are performed as described previously (Muneoka et al, 1986) with slight modifications (Gruber et al, 1998). All microinjections can be performed on embryos ranging from ED 10 through ED 13, when it is possible to visualize the body through the extraembryonic membranes.
  • Timed- pregnant female mice are anesthetized with an intraperitoneal injection of 0.2 ml/lOg body weight of Avertin (consisting of 2.5g 2,2,2-tribromoethanol, 5 ml 2-methyl- butanol (Aldrich) and 195ml sterile dH 2 0). Both uterine horns are exposed using a midline abdominal incision.
  • Access to the embryos can be accomplished by a longitudinal cut through the uterine myometrium.
  • the myometrium is then pulled back to the base of the placenta, leaving the embryos, with extraembryonic membranes intact, exposed to the abdominal cavity.
  • Embryos are washed copiously with sterile saline both before and after injection.
  • the abdominal cavity is bathed in penicillin G lOOU/ml + streptomycin lOO ⁇ g/ml in sterile saline before the abdomen is closed with a running 7-0 silk suture.
  • the mother is kept at 37°C and monitored until she has recovered from surgery.
  • the advantage of using Avertin as an anesthesia is that the recovery time is shorter, usually 4 to 6 hrs.
  • embryos are cryopreserved for immunohistochemistry as described (Gruber et al, 1998; Kitten et al, 1987). This procedure entails washing the embryos in PBS and fixing by perfusion in 4% buffered paraformaldehyde/PBS, prior to an incubation in the same fixative for 2 hr at 4°C. Following several PBS washes, the embryos are passed through a graded series of sucrose solutions prior to embedding in a 1:1 ratio of Aquamount/OTC (Miles) medium on a solid block of dry ice.
  • Miles Aquamount/OTC
  • Cryostat lO ⁇ m sections are cut and rinsed in PBS before being neutralized in 50 mM NH 4 C1/PBS for 5 min. Tissue is permeabilized and blocked in PBT (1.0% Triton X-100/PBS), 3% BSA (Sigma) and 10% normal goat serum for 25 min at room temperature. Sections are stained for one or more of the following: QH1, 2G6, TAC1, 109-19, 492-4A5, MF20, ⁇ -sarcomeric actin, cTnl, MLC- 2a, MLC-2v and ⁇ -galactosidase (5'3' Inc.) antibodies, depending upon species of the transplanted cells.
  • FITC-conjugated secondary antibodies are obtained from Jackson Immuno Research Labs, Inc. Slides are imaged as described (Eisenberg et al, 1997) on a Bio-Rad MRC-600 confocal connected to a Zeiss Axiophot inverted microscope.
  • Confluent cultures of bone marrow-derived cardiomyocytes are harvested following trypsin/EDTA treatment to obtain a single cell suspension in sterile Dulbecco's phosphate buffered saline (DPBS).
  • DPBS Dulbecco's phosphate buffered saline
  • the suspension is injected into adult heart as described previously, with minor modifications (Rockman et al, 1991). Specifically, eight to twelve- week old adult mice are anesthetized with an intraperitoneal injection of 0.2 ml/lOg body weight of Avertin (consisting of 2.5g 2,2,2-tribromoethanol, 5 ml 2-methyl-butanol and 195ml sterile dH 2 0).
  • the animal is intubated, with positive-pressure ventilation being maintained using a Harvard murine ventilator (model 687) set at a tidal volume of 0.2 ml and respiratory rate of 110/min.
  • the murine heart is exposed by a small incision in the second intercostal space at the left upper sternal border.
  • cells are injected directly into the ventricular myocardium through a 30-gauge double-beveled needle connected to a plastic syringe. Approximately 1 x 10 4 to 10 x 10 4 cells are delivered in a volume of 2 to 3 ⁇ l.
  • the chest cavity is then closed with a 7-0 nylon suture. Following extubation and evacuation of the pneumothorax, the mouse is kept at 37°C and monitored until it has recovered from surgery.
  • TEM transmission electron microscopy examination
  • adult hearts are be harvested, washed in buffer (0.1 mol/L sodium phosphate, pH 7.3) and fixed overnight in 2.5% glutaraldehyde (Eisenberg and Bader, 1996).
  • hearts are stained for ⁇ -gal activity as described (Eisenberg and Markwald, 1997).
  • the product of this reaction is an electron-dense precipitate which can be detected with TEM.
  • the tissue is vibratome sectioned as described (Eisenberg et al, 1997) and the resulting 200 ⁇ m slices is embedded into LX-112 resin (Eisenberg and Bader, 1996). Ultrathin 60 nm sections is examined under a JEOL electron microscope (JEOL, Inc.).
  • JEOL, Inc. For cells labeled with the GFP adenovirus, sections are stained with the GFP primary antibody followed by an immunogold labeled secondary antibody.
  • the identified bone marrow cells with cardiac potential are early precursor cells. This was shown using a technique for isolating primitive hematopoietic cells.
  • 5- Fluorouracil (5-FU) is a cell cycling drug that specifically eliminates dividing cells.
  • HSCs that are in GI phase of the cell cycle incorporate 5-FU metabolites and thus die as they enter the S phase (Hodgson and Bradley, 1979). It is known that pluriopotent HSCs are quiescent and thus resistant to the drug. Hence, treatment of bone marrow cultures selectively enriches for this cell type (Lerner and Harrison, 1990). Embryonic day 14 (ED 14) quail bone marrow cells were isolated. HSC-containing nonadherent and adherent (stromal) cell population were both treated with high doses (25 ⁇ g/ml) of 5-FU for 24 hours. The cultures were then washed several times with PBS to remove the 5-FU.
  • the cultures were then incubated in a medium containing retinoic acid, stem cell factor, bFGF, FGF-4, endothelin-1, TGF ⁇ , and either aFGF or endothelial cell growth factor as described above to promote cardiomyocyte differentiation.
  • the cultures were then fluorescently stained using antibodies to sarcomeric myosin heavy chain.
  • the majority of the nonadherent cells and stromal cells plated were killed by the second day of treatment. Of the surviving cells in the stromal cultures, no cardiac phenotype was observed following treatment with the combination of growth factors described above. Virtually all of the pluripotent HSCs, the surviving cells from among the nonadherent cell cultures, differentiated into cardiomyocytes as evidenced by positive reactivity for sarcomeric myosin.
  • Nonadherent bone marrow stem cells were obtained from adult ICR mice (10 weeks old) without selecting for 5-FU resistance. The cells were labeled with the vital dye PKH26-GL as described above. Labeled HSC population were microinjected into the ventricles of ED9.0 ICR mouse embryos. Embryos were allowed to develop in ex ovo cultures as described above. Labeled adherent bone marrow cells were also injected as controls. Following 24 hours in culture, embryos were harvested, cryopreserved, and sectioned for immunohistochemistry. Even after only 24 hours in culture, some of the nonadherent HSCs incorporated into the ventricular tissue and began to express sarcomeric myosin. Those that were found outside the heart did not express the protein. Conversely, the adherent cells did not graft well into heart tissue and did not express the myocyte proteins. These results show that bone marrow cells can be grafted into heart tissue.
  • RT-PCR reverse-transcriptase polymerase chain reaction
  • oligonucleotide primers for either of the cardiac transcription factors Nkx2.5 (5'-CCTTCCCCGGCCCCTACTAC-3') (SEQ ID NO.: 1) or GATA4 (5'-CTCCTACTCCACCCCTTACC-3' (SEQ ID NO:2) and 5'GCCCTGTGCCATCTCTCCTC-3' (SEQ ID NO:3)) were used.
  • Nkx2.5 5'-CCTTCCCCGGCCCCTACTAC-3'
  • GATA4 5'-CTCCTACTCCACCCCTTACC-3'
  • 5'GCCCTGTGCCATCTCTCCTC-3' 5'GCCCTGTGCCATCTCTCCTC-3'
  • nonadherent quail bone marrow cells were isolated as described above and then treated with a high dose of 5-fluorouracil (5-FU) as in Example 7.
  • the cells were cultured subsequently in medium containing 100 ng/ml stem cell factor (SCF), 100 ng/ml FLT3/FLK2 and 20 ng/ml IL-11.
  • SCF stem cell factor
  • FLT3/FLK2 FLT3/FLK2
  • 20 ng/ml IL-11 20 ng/ml IL-11.
  • the cells were then expanded for one week to ten days, resulting in approximately a 1000 fold increase in the number of HSC cells.
  • approximately 10 7 bone marrow cells were obtained from a dozen quail embryos, and approximately 1000 cells survived the 5-FU treatment. This cell yield increased to greater than 10 6 after 10 days of expansion.
  • nonadherent bone marrow stem cells were isolated from adult mice (C57BL/6) and labeled with the vital dye PKH26-GL.
  • Labeled HSC cells were microinjected into the left ventricles of 12-week old C57BL/6 mice. Two weeks later, the animals were sacrificed, and the hearts isolated, cryopreserved, and sectioned for immunohistochemistry.
  • Nonadherent HSCs incorporated into the ventricular tissue, and some of the cells expressed the cardiac-specific marker, ventricular myosin light chain-2 (MLC2v).
  • MLC2v ventricular myosin light chain-2
  • fluorescent dye labeled HSCs were incorporated into MLC2v-positive ventricular cardiomyocytes.
  • a small number of vital dye labeled cells were also MLC2v positive.
  • Embryonic mesodermal stem cells fully differentiate into cardiomyocytes upon co-culture with explants of cardiac tissue fragments from tubular heart stage embryos.
  • virally labeled QCE6 cells were co-cultured with a HH stage 16 quail ventricular tissue fragment. After 48 hours of incubation, the cultures were dual stained for both sarcomeric myosin and ⁇ -galactosidase (a marker for the viral label). A population of the ⁇ -galactosidase reactive cells were also reactive for sarcomeric myosin. Only those QCE6 cells that integrated into the ventricular tissue underwent cardiac differentiation.
  • bone marrow cells can be co-cultured with embryonic stem cells or embryonic heart tissue.
  • embryonic stem cell line WW6 which is of C57BL/6 background.
  • the cells are obtained from ⁇ -gal positive ROSA26 mice. Aggregates are produced using hanging drop cultures. (See Eisenberg and Markwald, 1997).
  • Purified HSCs and ES cells are mixed at ratios of 1 :9 to 1:19 and suspended in medium at concentrations of 1.25 to 2.5 X 10 6 cells/ml and distributed in 20 ⁇ l drops on the lids of sterile, 100 mm Petri dishes, The lids are inverted onto the dishes, each containing 2ml of sterile PBS. Following 48 hours of incubation, cell aggregates are transferred to new Petri dishes containing medium and incubated for 4 additional days. These aggregates are routinely observed microscopically to determine the extent of cell differentiation (i.e., presence of beating cells). To examine individual cells, the aggregates are partially dissociated by gently pipeting after treatment with 0.25% trypsin for 10 min.
  • the resulting cell clumps are suspended in medium and plated into chamber slides for 12 hours prior to staining for both ⁇ -gal and individual sarcomeric proteins.
  • Reagents specific for ⁇ -gal are commercially available as either rabbit polyclonal (5Prime- 3Prime) or mouse monoclonal (Sigma) antibodies, which can be used in conjunction with either the monoclonal MF20 or polyclonal 492-4A5 myosin antibodies, respectively.
  • Secondary antibodies specific for rabbit or mouse primary reagents are labeled with either fluorescein or Cy5 to detect protein expression.
  • ED 12 embryos are extracted from timed pregnant C57BL/6 mice and placed in PBS.
  • the visceral yolk sac and amnion are removed, and the entire heart tube removed and placed in fresh PBS.
  • the hearts are then microdissected to obtain tissue fragments from either atrial or ventricular regions, with great care made to ensure that individual explants are segment specific.
  • the individual fragments are then slit along one side and placed endocardial side down in individual wells of fibronectin-coated chamber slides, a ta density of 2-3 region-specific fragments per well.
  • the segmental identity of the cultured tissue are verified by immunostaining for both MLC2a and MLC2v, which are atrial-specific and ventricular- specific proteins, respectively (O'Brien et al, 1993; Kubalak et al, 1994).
  • Atrial and ventricular fragments are incubated for four hours to facilitate attachment to he fibronectin substrate, prior to the addition of 10 5 purified HSCs obtained from adult ROSA26 mouse bone marrow. Cultures are incubated at 37°C for up to four days and microscopically analyzed daily for contractility prior to fixation of the tissue. After fixation, the tissue are dual stained for both ⁇ -gal (to identify the bone marrow derived cells) and either MF20, MLC2a, or MLC2v. In parallel, purified HSCs are cultured alone, treated with cardiac inducing growth factors and stained for either MLC2a or MLC2v.
  • Cardiomyocytes derived from bone marrow cells co-cultured with either embryonic stem cells or embryonic heart tissue can also be examined using electron microscopy as described above in Example 6.
  • mouse HSCs To promote differentiation of hematopoietic cells to myeloid-lymphoid stem cell intermediate, culture conditions for mouse HSCs were modified. Specifically, the mouse HSCs were grown in Iscove's Modified Dulbecco's Medium (Gibco/BRL) with 5% fetal bovine serum (Sigma) + 50 ⁇ M 2-ME ( ⁇ -mercaptoethanol; Sigma) + 100 ng/ml GM-CSF (peproTech) for six days at 37°C in 5% CO 2 . This treatment selectively expands this population, giving rise to typical, myeloid-lymphoid stem cell aggregates. These aggregates are loosely adherent to tissue culture plastic and therefore can easily be dislodged and harvested by gentle pipetting.
  • Iscove's Modified Dulbecco's Medium Gibco/BRL
  • 2-ME ⁇ -mercaptoethanol
  • peproTech 100 ng/ml GM-CSF
  • the aggregates were then transferred to a tissue culture dish containing Iscove's Modified Dulbecco's Medium (Gibco/BRL) + 20% fetal bovine serum (Sigma). Under these conditions, cells released from the aggregates attached to the plastic and exhibited a fibroblast morphology.
  • fibronectin-coated Human plasma fibronectin at 10 ⁇ g/cm 3 ; Collaborative
  • tissue culture plastic vessels containing 50% Iscove's Modified Dulbecco's Medium (Gibco/BRL) + 50% Wntl 1 (or, alternatively, any Wnt of the class Wnt 5a) conditioned medium + 20% fetal bovine serum (Sigma) + 50 ⁇ M 2-ME + retinoic acid (2 X 10 "8 M; Sigma) + FGF-4 (100 ng/ml; Sigma) + bFGF (100 ng/ml; PeproTech) + IL-2 +IL-15 (both at 10 ng/ml; PeproTech) + IL-10 (50 ng/ml; PeproTech) + SCF (100 ng/ml; PeproTech) + TGF ⁇ (5ng/ml; Sigma) + TGF ⁇ l (10 ng/ml R & D Systems) + endothelin (1
  • Example 14 the aggregates of typical, myeloid-lymphoid stem cells were cultured under conditions that promoted a skeletal muscle phenotype. Specifically, the aggregates isolated by the methods described in Example 14 were transferred to a tissue culture dish containing Iscove's Modified Dulbecco's Medium (Gibco/BRL) + 20% fetal bovine serum (Sigma).
  • Iscove's Modified Dulbecco's Medium Gibco/BRL
  • 20% fetal bovine serum Sigma
  • fibronectin-coated Human plasma fibronectin at 10 ⁇ g/cm 3 ; Collaborative tissue culture plastic vessels containing Iscove's Modified Dulbecco's Medium (Gibco/BRL)+ 20% fetal bovine serum (Sigma) + 50 ⁇ M 2-ME + retinoic acid (2 X 10 "8 M; Sigma) + bFGF (100 ng/ml; PeproTech) + IL-2 +IL-15 (both at 10 ng/ml; PeproTech) + SCF (100 ng/ml; PeproTech) + IGF-1 (50 ng/ml; Sigma) + ECGS (100 ⁇ g/ml; Sigma) + PDGF (10 ng/ml; Sigma) + 3,3',5-triiodo-L-thyronine (20ng/ml; Sigma) + cAMP (5 X 10
  • nonadherent bone marrow stem cells are isolated from adult mice (C57BL/6) and labeled with the vital dye PKH26-GL.
  • Labeled HSC cells are microinjected into the leg muscle of a 12-week old C57BL/6 mice. Two weeks later, the animals are sacrificed, and the injected muscle is isolated, cryopreserved, and sectioned for immunohistochemistry. The tissue is analyzed to determine whether nonadherent HSCs incorporated into the skeletal muscle tissue, and whether the cells expressed skeletal muscle-specific markers, such as MyoD or skeletal muscle-specific myosin.
  • the number of vital dye labeled cells that also show a skeletal muscle morphology (i.e., multinucleated and striated) or skeletal muscle-specific markers are determined. These results are designed to show that adult bone marrow cells can be engrafted successfully into adult skeletal muscle tissue and that a population of the HSC cells undergo skeletal muscle cell differentiation within the permissive environment.
  • various publications are referenced. The disclosures of these publications in their entireties are hereby inco ⁇ orated by reference into this application in order to more fully describe the state of the art to which this invention pertains.
  • Eisenberg, C. A., Gourdie, R. G., and Eisenberg, L. M. (1997). Wnt-11 is expressed in early avian mesoderm and required for the differentiation of the quail mesoderm cell line QCE-6. Development 124, 525-536.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne un procédé permettant de promouvoir la différenciation d'une cellule souche en un cardiomyocyte ou une cellule de muscle squelettique, qui consiste à recueillir chez un donneur une cellule souche, de préférence une cellule souche hématopoïétique, à potentiel de cardiomyocyte ou de cellule de muscle squelettique, et à mettre en contact cette cellule souche avec un facteur de croissance ou une combinaison de facteurs de croissance. L'invention concerne en outre une population de cardiomyocytes ou de cellules de muscle squelettique dérivés selon le procédé décrit, des cellules souches non embryonnaires à potentiel de cardiomiocyte ou de cellule de muscle squelettique, et des cellules souches hématopoïétiques embryonnaires ou non embryonnaires. L'invention concerne en outre une composition, qui renferme les cellules souches et une combinaison de facteurs de croissance, selon des quantités et dans des conditions permettant de promouvoir la différenciation des cellules souches en cardiomyocytes ou en cellules de muscle squelettique. L'invention concerne également des procédés relatifs à l'utilisation des cellules considérées.
PCT/US1999/021916 1998-09-21 1999-09-21 Cellules non hematopoietiques, y compris les cardiomyocytes et les cellules de muscle squelettique, que l'on derive de cellules souches hematopoietiques, et procedes relatifs a leur elaboration et a leur utilisation Ceased WO2000017326A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU60562/99A AU6056299A (en) 1998-09-21 1999-09-21 Non-hematopoietic cells, including cardiomyocytes and skeletal muscle cells, derived from hematopoietic stem cells and methods of making and using them

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10124098P 1998-09-21 1998-09-21
US60/101,240 1998-09-21

Publications (1)

Publication Number Publication Date
WO2000017326A1 true WO2000017326A1 (fr) 2000-03-30

Family

ID=22283655

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/021916 Ceased WO2000017326A1 (fr) 1998-09-21 1999-09-21 Cellules non hematopoietiques, y compris les cardiomyocytes et les cellules de muscle squelettique, que l'on derive de cellules souches hematopoietiques, et procedes relatifs a leur elaboration et a leur utilisation

Country Status (2)

Country Link
AU (1) AU6056299A (fr)
WO (1) WO2000017326A1 (fr)

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001021766A3 (fr) * 1999-09-23 2001-06-28 Cell Science Therapeutics Procedes et dispositifs permettant d'obtenir des cellules de lignee non hematopoietique a partir de cellules de progeniteurs hematopoietiques
WO2003074684A1 (fr) * 2002-03-07 2003-09-12 Takeda Chemical Industries, Ltd. Cellules capables de se differencier en cellules de type myocarde
WO2003055989A3 (fr) * 2001-12-21 2003-10-30 Mount Sinai Hospital Corp Compositions cellulaires et procedes de preparation et d'utilisation associes
WO2003023022A3 (fr) * 2001-09-11 2004-03-25 Science Park Raf Spa Procede d'induction de la differentiation des cellules endotheliales dans des cardiomyocites
EP1390473A4 (fr) * 2001-04-13 2005-04-06 Anterogen Co Ltd Methodes et reactifs pour transplantation cellulaire
EP1590448A4 (fr) * 2003-01-23 2006-03-29 Anterogen Co Ltd Methode de preparation cellulaire pour transplantation
US7045353B2 (en) 2000-08-01 2006-05-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Directed differentiation of human embryonic cells
EP1619242A4 (fr) * 2003-03-25 2006-09-06 Japan Science & Tech Agency Commande de l'induction de la differenciation de cellules souches et de la capacite de differenciation
US7297538B2 (en) 2001-04-13 2007-11-20 Cardio3 S.A. Encapsulated cell indicator system
CN101085983A (zh) * 2006-06-06 2007-12-12 刘永详 自体干细胞、由其转化而成的目标细胞及其用途
EP2090308A1 (fr) * 2008-02-15 2009-08-19 Bone Therapeutics Composition pharmaceutique pour le traitement ou la prévention de maladies ostéo-articulaires
WO2009101210A1 (fr) * 2008-02-15 2009-08-20 Bone Therapeutics Composition pharmaceutique destinée à traiter et/ou à prévenir des maladies ostéo-articulaires
JP2009539378A (ja) * 2006-06-09 2009-11-19 アントフロゲネシス コーポレーション 胎盤環境及び幹細胞を培養するためのその使用
US7627373B2 (en) 2002-11-30 2009-12-01 Cardiac Pacemakers, Inc. Method and apparatus for cell and electrical therapy of living tissue
US7682607B2 (en) 2001-05-01 2010-03-23 The Regents Of The University Of California Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
US7718379B2 (en) 2001-10-30 2010-05-18 The Peter Maccallum Cancer Institute Identifying haematopoietic stem cells based on cell surface markers
US7811820B2 (en) 2003-01-10 2010-10-12 Baylor College Of Medicine Smooth muscle cell differentiation with CRP, SRF and GATA factors
EP2270146A1 (fr) * 2002-02-06 2011-01-05 Sanbio, Inc. Méthode de différenciation/d'induction de cellules interstitielles de moelle osseuse en cellules nerveuses et en cellules musculaires du squelette par transfert du gène notch
US7960173B2 (en) 2004-06-10 2011-06-14 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Cardiac conduction system cells and uses thereof
US8158121B2 (en) 1997-07-14 2012-04-17 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
EP2270196B1 (fr) 2004-05-11 2016-04-20 Axiogenesis Ag Methodes pour la découverte de médicaments utilisant des cellules différentiées in vitro
US9446065B2 (en) 2008-02-15 2016-09-20 Bone Therapeutics Pharmaceutical composition for use in the treatment and/or the prevention of osteoarticular diseases
WO2022195589A2 (fr) 2021-03-16 2022-09-22 Yeda Research And Development Co. Ltd. Méthodes et dispositifs permettant le développement embryonnaire de souris ex-utéro
US11608486B2 (en) 2015-07-02 2023-03-21 Terumo Bct, Inc. Cell growth with mechanical stimuli
US11613727B2 (en) 2010-10-08 2023-03-28 Terumo Bct, Inc. Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
US11629332B2 (en) 2017-03-31 2023-04-18 Terumo Bct, Inc. Cell expansion
US11634677B2 (en) 2016-06-07 2023-04-25 Terumo Bct, Inc. Coating a bioreactor in a cell expansion system
US11667876B2 (en) 2013-11-16 2023-06-06 Terumo Bct, Inc. Expanding cells in a bioreactor
US11667881B2 (en) 2014-09-26 2023-06-06 Terumo Bct, Inc. Scheduled feed
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11795432B2 (en) 2014-03-25 2023-10-24 Terumo Bct, Inc. Passive replacement of media
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
US12043823B2 (en) 2021-03-23 2024-07-23 Terumo Bct, Inc. Cell capture and expansion
US12152699B2 (en) 2022-02-28 2024-11-26 Terumo Bct, Inc. Multiple-tube pinch valve assembly
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999003973A1 (fr) * 1997-07-14 1999-01-28 Osiris Therapeutics, Inc. Regeneration du muscle cardiaque a l'aide de cellules souche mesenchymateuses

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999003973A1 (fr) * 1997-07-14 1999-01-28 Osiris Therapeutics, Inc. Regeneration du muscle cardiaque a l'aide de cellules souche mesenchymateuses

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
BRUDER S P ET AL: "MESENCHYMAL STEM CELLS IN BONE DEVELOPMENT, BONE REPAIR, AND SKELETAL REGENERATION THERAPY", JOURNAL OF CELLULAR BIOCHEMISTRY,US,NEW YORK, NY, vol. 56, 1994, pages 283-294, XP002913340 *
EISENBERG C A AND MARKWALD R R: "Mixed cultures of avian blastoderm cells and the quail mesoderm cell line QCE-6 provide evidence for the pluripotentiality of early mesoderm", DEVELOPMENTAL BIOLOGY, vol. 191 (2), 15 November 1997 (1997-11-15), pages 167-181, XP000866328 *
EISENBERG C A ET AL.,: "Wnt-11 is expressed in early avian mesoderm and required for the differentiation of the quail mesoderm cell line QCE-6.", DEVELOPMENT, vol. 124, no. 2, 1997, pages 525 - 536, XP000865667 *
FERRARI G ET AL.,: "Bone marrow transplantation as source of myogenic progenitors: Differentiation of stem cells into muscle.", CELL TRANSPLANTATION, vol. 8, no. 2, April 1999 (1999-04-01), pages p195, XP000869901 *
FERRARI G ET AL: "Muscle regeneration by bone marrow -derived myogenic progenitors [see comments] [published erratum appears in Science 1998 Aug 14;281(5379):923]", SCIENCE,US,AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, vol. 279, pages 1528-1530, XP002098163, ISSN: 0036-8075 *
KESSLER PD; BYRNE BJ: "Myoblast cell grafting into heart muscle: cellular biology and potential applications", ANNU REV PHYSIOL (UNITED STATES), vol. 61, 1999, pages 219-42, XP000865708 *
KLUG M G ET AL: "GENETICALLY SELECTED CARDIOMYOCYTES FROM DIFFERENTIATING EMBRYONIC STEM CELLS FORM STABLE INTRACARDIAC GRAFTS", JOURNAL OF CLINICAL INVESTIGATION,US,NEW YORK, NY, vol. 98, no. 1, 1 July 1996 (1996-07-01), pages 216-224, XP000670716, ISSN: 0021-9738 *
LEOR J ET AL: "Transplantation of fetal myocardial tissue into the infarcted myocardium of rat. A potential method for repair of infarcted myocardium?", CIRCULATION,US,AMERICAN HEART ASSOCIATION, DALLAS, TX, vol. 94, no. 9, SUPPL, 1 November 1996 (1996-11-01), pages 11332-11336, XP002078687, ISSN: 0009-7322 *
MURRY C E ET AL: "Skeletal myoblast transplantation for repair of myocardial necrosis", JOURNAL OF CLINICAL INVESTIGATION,US,NEW YORK, NY, vol. 98, no. 11, 1 December 1996 (1996-12-01), pages 2512-2523, XP002078686, ISSN: 0021-9738 *
TOMITA S ET AL.,: "Autologous transplantation of bone marrow cells improves damaged heart function.", CIRCULATION, vol. 100 (19 SUPPL.), 9 November 1999 (1999-11-09), pages pII247-II256, XP000869909 *
TOMITA S ET AL.,: "Autotransplanted mesenchymal stem cells improve function after a myocardial infarction", CIRCULATION, vol. 98, no. (17 SUPPL.), 27 October 1998 (1998-10-27), pages pI200, XP000870314 *
WAKITANI S ET AL.,: "Myogenic cells derived from rat bone marrow mesenchymal stem cells exposed to 5-azacytidine.", MUSCLE & NERVE, vol. 18, no. 12, 1995, pages 1417-1426, XP000869895 *

Cited By (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852575B2 (en) 1997-07-14 2014-10-07 Mesoblast International Sarl Cardiac muscle repair or regeneration using bone marrow-derived stem cells
US8852574B2 (en) 1997-07-14 2014-10-07 Mesoblast International Sarl Cardiac muscle repair or regeneration using bone marrow-derived stem cells
US8852571B2 (en) 1997-07-14 2014-10-07 Mesoblast International Sarl Cardiac muscle regeneration using mesenchymal stem cells
US8852573B2 (en) 1997-07-14 2014-10-07 Mesoblast International Sarl Cardiac muscle repair or regeneration using bone marrow-derived stem cells
US8852572B2 (en) 1997-07-14 2014-10-07 Mesoblast International Sarl Cardiac muscle repair or regeneration using bone marrow-derived stem cells
US8158121B2 (en) 1997-07-14 2012-04-17 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
US8158120B2 (en) * 1997-07-14 2012-04-17 Osiris Therapeutics, Inc. Cardiac muscle repair or regeneration using bone marrow-derived stem cells
US8852570B2 (en) 1997-07-14 2014-10-07 Mesoblast International Sarl Cardiac muscle regeneration using mesenchymal stem cells
WO2001021766A3 (fr) * 1999-09-23 2001-06-28 Cell Science Therapeutics Procedes et dispositifs permettant d'obtenir des cellules de lignee non hematopoietique a partir de cellules de progeniteurs hematopoietiques
US7772001B2 (en) 2000-08-01 2010-08-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Directed differentiation of embryonic stem cells into an endoderm cell
US7045353B2 (en) 2000-08-01 2006-05-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Directed differentiation of human embryonic cells
EP1390473A4 (fr) * 2001-04-13 2005-04-06 Anterogen Co Ltd Methodes et reactifs pour transplantation cellulaire
KR100864123B1 (ko) * 2001-04-13 2008-10-16 (주)안트로젠 이식용 세포의 생산방법
US7297538B2 (en) 2001-04-13 2007-11-20 Cardio3 S.A. Encapsulated cell indicator system
KR100694963B1 (ko) * 2001-04-13 2007-03-14 (주)안트로젠 이식용 세포의 생산방법
US7682607B2 (en) 2001-05-01 2010-03-23 The Regents Of The University Of California Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
WO2003023022A3 (fr) * 2001-09-11 2004-03-25 Science Park Raf Spa Procede d'induction de la differentiation des cellules endotheliales dans des cardiomyocites
US7718379B2 (en) 2001-10-30 2010-05-18 The Peter Maccallum Cancer Institute Identifying haematopoietic stem cells based on cell surface markers
US7625752B2 (en) 2001-12-21 2009-12-01 Mount Sinai Hospital Cellular compositions and methods of making and using them
WO2003055989A3 (fr) * 2001-12-21 2003-10-30 Mount Sinai Hospital Corp Compositions cellulaires et procedes de preparation et d'utilisation associes
US11512284B2 (en) 2002-02-06 2022-11-29 Sanbio, Inc. Neural precursor cells expressing exogenous Notch intracellular domain
US8133725B2 (en) 2002-02-06 2012-03-13 Sanbio, Inc. Bone marrow stromal cells comprising a nucleic acid encoding a notch intracellular domain
EP2270146A1 (fr) * 2002-02-06 2011-01-05 Sanbio, Inc. Méthode de différenciation/d'induction de cellules interstitielles de moelle osseuse en cellules nerveuses et en cellules musculaires du squelette par transfert du gène notch
US8361456B2 (en) 2002-02-06 2013-01-29 Sanbio, Inc. Method of inducing differentiation of bone marrow stromal cells to neural precursor cells, neural precursor cells, and uses thereof
US10196605B2 (en) 2002-02-06 2019-02-05 Sanbio, Inc. Treatment of CNS disorders using descendants of MSCS expressing an exogenous Notch intracellular domain
US9399046B2 (en) 2002-02-06 2016-07-26 Sanbio, Inc. Treatment of CNS disorders using descendants of MSCs expressing an exogenous Notch intracellular domain
US8969078B2 (en) 2002-02-06 2015-03-03 Sanbio, Inc. Neural precursor cells produced from bone marrow stromal cells containing an exogenous nucleic acid encoding a notch intracellular domain (NICD)
WO2003074684A1 (fr) * 2002-03-07 2003-09-12 Takeda Chemical Industries, Ltd. Cellules capables de se differencier en cellules de type myocarde
US7627373B2 (en) 2002-11-30 2009-12-01 Cardiac Pacemakers, Inc. Method and apparatus for cell and electrical therapy of living tissue
US7811820B2 (en) 2003-01-10 2010-10-12 Baylor College Of Medicine Smooth muscle cell differentiation with CRP, SRF and GATA factors
EP1590448A4 (fr) * 2003-01-23 2006-03-29 Anterogen Co Ltd Methode de preparation cellulaire pour transplantation
EP1619242A4 (fr) * 2003-03-25 2006-09-06 Japan Science & Tech Agency Commande de l'induction de la differenciation de cellules souches et de la capacite de differenciation
EP2270196B1 (fr) 2004-05-11 2016-04-20 Axiogenesis Ag Methodes pour la découverte de médicaments utilisant des cellules différentiées in vitro
US7960173B2 (en) 2004-06-10 2011-06-14 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Cardiac conduction system cells and uses thereof
CN101085983A (zh) * 2006-06-06 2007-12-12 刘永详 自体干细胞、由其转化而成的目标细胞及其用途
JP2009539378A (ja) * 2006-06-09 2009-11-19 アントフロゲネシス コーポレーション 胎盤環境及び幹細胞を培養するためのその使用
WO2009101210A1 (fr) * 2008-02-15 2009-08-20 Bone Therapeutics Composition pharmaceutique destinée à traiter et/ou à prévenir des maladies ostéo-articulaires
US9415036B2 (en) 2008-02-15 2016-08-16 Bone Therapeutics Pharmaceutical composition for use in the treatment or prevention of osteoarticular diseases
US9446065B2 (en) 2008-02-15 2016-09-20 Bone Therapeutics Pharmaceutical composition for use in the treatment and/or the prevention of osteoarticular diseases
US9872876B2 (en) 2008-02-15 2018-01-23 Bone Therapeutics Pharmaceutical composition for use in the treatment and/or the prevention of osteoarticular diseases
EP2090308A1 (fr) * 2008-02-15 2009-08-19 Bone Therapeutics Composition pharmaceutique pour le traitement ou la prévention de maladies ostéo-articulaires
AU2009214044B2 (en) * 2008-02-15 2014-08-14 Bone Therapeutics Pharmaceutical composition for use in the treatment or prevention of osteoarticular diseases
US11773363B2 (en) 2010-10-08 2023-10-03 Terumo Bct, Inc. Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
US11746319B2 (en) 2010-10-08 2023-09-05 Terumo Bct, Inc. Customizable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
US11613727B2 (en) 2010-10-08 2023-03-28 Terumo Bct, Inc. Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
US11708554B2 (en) 2013-11-16 2023-07-25 Terumo Bct, Inc. Expanding cells in a bioreactor
US11667876B2 (en) 2013-11-16 2023-06-06 Terumo Bct, Inc. Expanding cells in a bioreactor
US11795432B2 (en) 2014-03-25 2023-10-24 Terumo Bct, Inc. Passive replacement of media
US11667881B2 (en) 2014-09-26 2023-06-06 Terumo Bct, Inc. Scheduled feed
US12065637B2 (en) 2014-09-26 2024-08-20 Terumo Bct, Inc. Scheduled feed
US11608486B2 (en) 2015-07-02 2023-03-21 Terumo Bct, Inc. Cell growth with mechanical stimuli
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
US11634677B2 (en) 2016-06-07 2023-04-25 Terumo Bct, Inc. Coating a bioreactor in a cell expansion system
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US12077739B2 (en) 2016-06-07 2024-09-03 Terumo Bct, Inc. Coating a bioreactor in a cell expansion system
US11999929B2 (en) 2016-06-07 2024-06-04 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11702634B2 (en) 2017-03-31 2023-07-18 Terumo Bct, Inc. Expanding cells in a bioreactor
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
US11629332B2 (en) 2017-03-31 2023-04-18 Terumo Bct, Inc. Cell expansion
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
US12359170B2 (en) 2017-03-31 2025-07-15 Terumo Bct, Inc. Expanding cells in a bioreactor
WO2022195589A2 (fr) 2021-03-16 2022-09-22 Yeda Research And Development Co. Ltd. Méthodes et dispositifs permettant le développement embryonnaire de souris ex-utéro
US12043823B2 (en) 2021-03-23 2024-07-23 Terumo Bct, Inc. Cell capture and expansion
US12152699B2 (en) 2022-02-28 2024-11-26 Terumo Bct, Inc. Multiple-tube pinch valve assembly
US12209689B2 (en) 2022-02-28 2025-01-28 Terumo Kabushiki Kaisha Multiple-tube pinch valve assembly
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device

Also Published As

Publication number Publication date
AU6056299A (en) 2000-04-10

Similar Documents

Publication Publication Date Title
WO2000017326A1 (fr) Cellules non hematopoietiques, y compris les cardiomyocytes et les cellules de muscle squelettique, que l'on derive de cellules souches hematopoietiques, et procedes relatifs a leur elaboration et a leur utilisation
RU2392315C2 (ru) Способ индукции дифференциации стволовых клеток в миокардиальные
KR101529317B1 (ko) 영장류 다능성 줄기 세포의 심근세포 계통 세포로의 분화
EP1444329B1 (fr) Cellules souches se transformant en cardiomyocytes a battements spontanes
RU2359030C1 (ru) Способ получения эндотелиальных клеток из эмбриональных стволовых клеток человека (варианты)
US20130266543A1 (en) Multipotent Adult Stem Cell Population
US20100166714A1 (en) Cardiovascular stem cells, methods for stem cell isolation, and uses thereof
JP4085062B2 (ja) 霊長類の胚性幹細胞から由来した内皮細胞
BR112015022770B1 (pt) Meio e sistema de cultivo da célula livre de xenógeno, livre de albumina, forma concentrada, métodos de diferenciação de células-tronco pluripotentes humanas, para a produção de mesenquimoangioblastos e sistema definido de cultivo da célula para diferenciação hematoendotelial das células- tronco pluripotentes humanas
US20120295347A1 (en) Methods and Compositions for Producing Endothelial Progenitor Cells from Pluripotent Stem Cells
JPWO2005063967A1 (ja) 哺乳動物の骨髄細胞または臍帯血由来細胞と脂肪組織を利用した心筋細胞の誘導
Fukuda Progress in myocardial regeneration and cell transplantation
US20050221482A1 (en) Methods and compositions for obtaining hematopoietic stem cells derived from embryonic stem cells and uses thereof
JP5174019B2 (ja) Ｇ−ｃｓｆを用いた心筋細胞への分化誘導方法
Kathiriya et al. Human alveolar Type 2 epithelium transdifferentiates into metaplastic KRT5+ basal cells during alveolar repair
KR100677054B1 (ko) 제대혈로부터 다분화능 전구세포를 분리하여 배양하는 방법 및 이의 분화 유도방법
KR20250075707A (ko) 심장 섬유아세포의 제조 방법
KR20240056604A (ko) 수임 심장 전구세포의 제조 방법
US20080241870A1 (en) Composition For Creating an Artificial Bone Marrow Like Environment and Use Thereof
WO2026013575A1 (fr) Modélisation de niches hématopoïétiques de développement d'embryon humain pour l'expansion ex vivo de cellules souches sanguines quasi-physiologiques
Aghami et al. ESC cardiac differentiation and applications
Kelley et al. Collection and Expansion of Stem Cells
Marshall The origin and regulation of haematopoietic stem cells during mammalian embryogenesis
WO2006085482A1 (fr) Facteur d'autoreplication et procede d’amplification d’une cellule souche hematopoietique
HK1143402A (en) Method of inducing differentiation into myocardial cells using g-csf

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase